



HAL
open science

Modulating undruggable targets to overcome cancer therapy resistance

Catherine Passirani, Giuseppe La Regina, Anne Vessieres, Wolfgang Link,
Romano Silvestri

► **To cite this version:**

Catherine Passirani, Giuseppe La Regina, Anne Vessieres, Wolfgang Link, Romano Silvestri. Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates, 2021, 60, pp.100788. 10.1016/j.drug.2021.100788 . hal-03527069

HAL Id: hal-03527069

<https://hal.science/hal-03527069v1>

Submitted on 18 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Modulating undruggable targets to overcome cancer therapy resistance

Catherine Passirani^a, Anne Vessières^b, Giuseppe La Regina^c, Wolfgang Link^{d,*}, Romano Silvestri^{c,*}

^aMicro et Nanomédecines Translationnelles, MINT, UNIV Angers, UMR INSERM 1066, UMR CNRS 6021, SFR ICAT, 49000, Angers, France.

^bSorbonne Université, CNRS, IPCM, 4 Place Jussieu, 75005, Paris, France.

^cLaboratory affiliated to Institut Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

^dInstituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029, Madrid, Spain.

*Corresponding authors

E-mail address: walink@iib.uam.es (W.L.); romano.silvestri@uniroma1.it (R.S.).

This paper is published in *Drug Resistance Updates*, Elsevier, 2021, pp.100788.

DOI : [10.1016/j.drug.2021.100788](https://doi.org/10.1016/j.drug.2021.100788)

This version is the author's version.

ABSTRACT

Many cancer patients frequently fail to respond to anti-cancer treatment due to therapy resistance which is the major obstacle towards curative cancer treatment. Therefore, identification of the molecular mechanisms underlying resistance is of paramount clinical and economic importance. The advent of targeted therapies based on a molecular understanding of cancer could serve as a model for strategies to overcome drug resistance. Accordingly, the identification and validation of proteins critically involved in resistance mechanisms represent a path towards innovative therapeutic strategies to improve the clinical outcome of cancer patients. In this review, we discuss emerging targets, small molecule therapeutics and drug delivery strategies to overcome therapy resistance. We focus on rational treatment strategies based on transcription factors, pseudokinases, nuclear export receptors and immunogenic cell death strategy. Historically, unliganded transcription factors and pseudokinases were considered undruggable while blocking the nuclear export e.g., through inhibition of the nuclear export receptor CRM1 was predicted as highly toxic. Recent success inhibiting Gli HIF-1 α , HIF-2 α and reactivating the tumor suppressive transcription factors p53 and FOXO illustrates the feasibility and power of this targeting approach. Similarly, progress has been made in modulating the activity of pseudokinase proteins implicated in therapy resistance including members of the Tribbles protein family. On the other hand, the recent clinical approval of Selinexor, a specific inhibitor of CRM-1, a protein that mediates the transport of cargos with leucine-rich nuclear export signals and known to be a driver of drug resistance, represents the proof-of-concept for inhibiting the nuclear export as a feasible strategy to overcome therapy resistance.

The ever-growing capacity to target resistance mechanisms with judiciously selected small molecules, some of which are being formulated within smart nanoparticles, will pave the way towards the improvement of the clinical outcome and realize the full potential of targeted therapies and immunotherapies.

Keywords: Cancer, drug resistance, therapeutic targets, drug development, nanomedicine

Introduction

Our understanding of the molecular basis of cancer has increased exponentially in the past 4 decades beginning with the discovery of oncogenes and tumor suppressor genes in the 1980s (Capdeville et al., 2002; Hanahan and Weinberg, 2011, 2000) and started to result in novel targeted treatments in 2001 with the FDA approval of the Imatinib (Capdeville et al., 2002). The molecular groundwork required to discover new anti-cancer medicines nowadays is significantly higher than in the case of the traditional chemotherapeutic drugs which were sometimes identified empirically without pre-existing knowledge of their molecular mechanism of action (Drews, 2000; Ferreira et al., 2015; Link, 2018) whereas others were rationally based (Assaraf, 2007; Gonene and Assaraf, 2012; Assaraf et al., 2014). The latest achievements of this new knowledge-based drug discovery paradigm are the immune checkpoint inhibitors (ICIs) which markedly improved the clinical outcome of several solid tumors (Diesendruck and

Benhar, 2017; Kon and Benhar, 2019; Leonetti et al., 2019; Dal Bo, 2020). However, the efficacy of virtually all these novel cancer therapies is limited by pre-existing or acquired drug resistance and, as a consequence, tumor relapse. Somewhat surprisingly, recent research revealed that chemotherapeutics, targeted and immunotherapeutic agents share many of the molecular mechanisms underlying drug resistance despite their distinct modes of action (Housman et al., 2014). The strategy to discover new medicines based on in-depth knowledge of the disease has just begun to impact the clinic in the last decade but it is safe to say that it is highly successful. In parallel, drug development technologies evolved to a point that enables targeting proteins that were historically considered as intractable (Dang et al., 2017). Ras proteins represent a paradigmatic example of this process. Ras proteins were identified as oncogenes in the early 1980s and despite more than three decades of intensive effort to find specific inhibitors, they were perceived as undruggable

targets. Cumulative scientific and technological advances led to the development of allele-specific covalent inhibitors of KRAS (Moore et al., 2020) and to the approval of Sotorasib for its clinical use to treat patients with non-small-cell lung cancer (NSCLC) (Hong, D.S., et al, 2020). Accordingly, the molecular understanding of the mechanisms driving resistance will guide the path to develop means to overcome adaptive responses of the tumor and reap the full benefit of anti-cancer therapies.

Therapy resistance in cancer

Anticancer drug resistance has been recently declared as the biggest challenge in cancer treatment (Kozar et al., 2019) and as such surmounting such multidrug resistance modalities is of paramount importance in curative cancer therapeutics (Kathawala, et al., 2015; Iwasaki, et al., 1989; Narayanan, et al., 2020; Wang, et al., 2021). Many cancer patients fail to respond to therapy or develop resistance after initial treatment. If cancer cells become unresponsive to treatments, the patient relapses and eventually dies, generally due to metastasis. Therapy resistant tumors kill most cancer patients. Therapy resistance is known to occur for most of cancer types and for all modes of treatments including conventional chemotherapeutic drugs as well as for modern targeted drugs or ICIs (Groenendijk and Bernards, 2014). The treatment of advanced melanoma represents a paradigmatic example for this observation. For decades, treatment of metastatic melanoma included high-dose interleukin-2 or the alkylating chemotherapeutic drug dacarbazine (DTIC) (Ugurel et al., 2013), associated with response rates between 10-20% and severe side effects (Gray-Schopfer et al., 2007). The analysis of genomic alterations revealed that the kinase ERK is hyperactivated by mutated BRAF or mutated NRAS in up to 90% of human melanoma (Akbari et al., 2015; Gray-Schopfer et al., 2007). These findings provided the rationale to develop specific inhibitors of mutant BRAF and MEK, the kinase that acts downstream of BRAF to activate ERK, as therapeutics for advanced melanoma (Henriques et al., 2018). On the other hand, Nobel-prize awarded research on the regulation of T cell activity paved the way to develop ICIs aimed at unleashing anti-tumor T cell responses (Sharma and Allison, 2015). The BRAF inhibitors vemurafenib or dabrafenib and the MEK inhibitors trametinib, cobimetinib and binimetinib approved for the treatment of advanced melanomas with mutated BRAF, significantly improved the clinical success of the treatment (Luke et al., 2017; Luke and Hodi, 2013). The ICIs ipilimumab, nivolumab or pembrolizumab are widely used for the treatment of different tumor types nowadays, but due to its high mutational burden and consequently the presence of immunogenic tumor antigens, they have been particularly successful in melanoma (Davis et al., 2018). While both, small molecule inhibitors targeting components of the MAPK pathway and ICIs have yielded unprecedented clinical responses, most patients fail to respond or acquired resistance to these treatments (Kozar et al., 2019). As drug resistance limits the efficacy of all of these treatments via intrinsic or acquired resistance modalities, deciphering and targeting the underlying molecular mechanisms is of pivotal importance to reap the full benefit of anti-cancer therapeutics and develop combinatory and synergistic strategies.

Mechanisms of therapy resistance

Resistance mechanisms can operate within a cancer cell independent of other cells in a cell autonomous fashion (Gottesman, 2002). Conversely, non-cell-autonomous resistance mechanisms depend on the interaction of different cells (Ferreira et al., 2017). While intrinsic resistance refers to the innate capacity of cancer cells to escape therapy due to pre-existing factors, acquired resistance develops during the treatment to which the tumor was initially susceptible. These different types of resistance mechanisms operate in melanoma malignancies and most other cancer entities promoting a highly unresponsive phenotype. Therapeutic challenges drive tumor cells to exploit both genetic and phenotypic adaptive responses. Therapy resistant might occur upstream, downstream and at the level of the therapeutic drug target (Holohan et al., 2013). Before a drug can exert a therapeutic effect, it has to reach its cellular target in the

cancer cells or in the tumor microenvironment. Poor absorption, rapid metabolism or low tissue penetration might prevent a systemically administered drug to be at the side of action in the required concentration. This is especially true for lipophilic molecules which include most organic molecule drugs. Moreover, some drugs need to be metabolically processed to be active against cancer cells and therefore, inefficient activation can also limit the efficiency of drug treatment (Kaur et al., 2020, Aghi et al., 2000; RoCHAT, 2005; Townsend and Tew, 2003). As these pharmacokinetic host factors, decreased cellular influx via impaired influx transporters (Giovannetti, et al., 2017; Rothem, et al., 2002; Rothem, et al., 2003, 2004; Ifergan, et al., 2003; Kaufman, 2006) and increased efflux through multidrug efflux pumps, such as the ATP-binding cassette (ABC) superfamily (Borst et al., 1999; Choi, 2005) Li, et al., 2016; Wang, et al., 2021) represent therapy resistance mechanisms that operate upstream of the therapeutic drug target. Drug action also depends on the presence of the target and therefore alterations in the expression level (Assaraf, et al., 1989, 1992) or mutation of the target can render a cancer cell unresponsive to treatment (O'Hare et al., 2007). But even when the drug reaches its cellular target at a sufficient concentration, the cancer cell might still escape the therapeutic effects reactivating the same signalling pathway further downstream or activating alternative signal cascades (Paraiso et al., 2011). In addition, enhanced DNA damage repair (Lord and Ashworth, 2012) and dysfunctional apoptosis signalling (Mohammad et al., 2015) (Shahar and Larisch, 2020; Levin, et al., 2021; Gao, et al., 2021) can limit the efficacy of anti-cancer drugs. Several of these resistance mechanisms might co-exist in different cells that comprise a tumor. Consequently, tumor heterogeneity has been considered as a key driver of therapy resistance representing an ideal scenario to adapt to selective pressure arising from anti-cancer drug treatment. In particular, cancer stem cells (CSC), a small subpopulation of cells within the tumor with the ability to self-renew, differentiate and promote tumor growth have been suggested as the main source of drug resistance (Dean et al., 2005; Shibue and Weinberg, 2017) Erin, et al, 2020; Assaraf, Y.G., et al. 2019; Sharifzad, et al., 2019; Koren and Fuchs, 2016). CSCs are thought to be resistant to chemotherapy through the increased expression of drug efflux pumps, enhanced DNA repair and attenuated apoptotic signalling and therefore responsible for tumor relapse. CSCs have been identified and characterized in almost all solid tumors and their capacity to dynamically switch between CSC and non-CSC states has been shown recently (de Sousa e Melo et al., 2017; Shimokawa et al., 2017). This remarkable phenotypic plasticity suggests that drug resistance mechanisms do not need to be hardwired into the cancer genome, as phenotypic adaptation can mediate tumor cell survival. The capability to adapt through the transition between different cellular phenotypes increases the likelihood of cell survival upon anti-cancer therapy. Another phenotypic transition state is the epithelial-to-mesenchymal transition (EMT) which is closely associated with therapy resistance (Shibue and Weinberg, 2017) (Erin, et al., 2020; Santoro, et al., 2017). EMT is an evolutionary conserved reversible cellular program by which epithelial cells transiently adopt migratory and invasive properties typical of mesenchymal cells during embryonic development and wound healing, immune evasion and metastasis. Similar to the above-mentioned pharmacokinetic host factors, the tumor microenvironment can provide non-cell autonomous instructive signals to neighboring tumor cells promoting their survival under treatment pressure (Lu et al., 2012; Straussman et al., 2012; Trédan et al., 2007).

In this review, we aimed to focus on molecular target classes that have been shown to play a role in cancer drug resistance but were considered as undruggable such as transcription factors and pseudokinases or their inhibition was predicted to be associated with significant toxicity as the export receptor CRM1. Finally, among the cancer immunotherapy approaches recently introduced into the clinics and showing remarkable therapeutic potentials, it was discovered that some of the conventional chemotherapeutics could also exert immunomodulatory activities which might be

exploited to synergistically enhance their anticancer effects via the so-called “immunogenic cell death” (ICD) (Terenzi et al., 2016). We will show through significant examples how this strategy can also be employed to overcome multidrug resistance (MDR).

Emerging targets to overcome therapy resistance

In the knowledge-based drug discovery paradigm, target identification and target validation are the most innovative and riskiest steps of the drug development process and a major reason for drug attrition (Benson et al., 2006; Link, 2018). There is no reason to believe that this is any different in targeting therapy resistance. The molecular mechanisms outlined above reveal several obvious targets to be considered. As several adaptive responses to drug treatment rely on modifications of the drug target itself or reactivation of the same pathway further downstream or even redundant parallel signaling cascades, the targets to eradicate drug resistant tumors include many components of known oncogenic signaling pathways such as Her2, EGFR, PI3K, AKT, mTOR, Ras, Raf, Mek, Wnt and β -catenin. Inhibition of ATP-binding cassette (ABC) transporters responsible for enhanced drug efflux and MDR (Choi, 2005), the detoxification enzymes Glutathione S-transferases (GSTs) (Zhang et al., 2014) and uridine diphospho-glucuronosyltransferase (UGT) (Guillemette, 2003; Rowland et al., 2013) as well as the monooxygenase cytochrome P450s responsible for the activation of several prodrugs, are considered as possible therapeutic strategies to overcome therapy resistance. Targeting components of signaling pathways such as the Notch, Wnt or the Hedgehog pathways involved in the maintenance of stem cell properties have been proposed as a therapeutic modality to eliminate the CSC subpopulation within the tumor as a source of resistance and relapse. Recently, some emerging targets in cancer drug resistance have been discussed (Kumar et al., 2019).




Fig. 1. Overview of the emerging therapeutic targets discussed in the current review and their functional role in cellular signaling.

In the current review article, we focus on several therapeutic targets that have emerged in recent years and represent promising options to surmount therapy resistance in cancer. These targets including pseudokinases, unliganded transcription factors and nuclear export receptors (Fig. 1) have been traditionally considered as difficult to target or “undruggable” as they might lack binding pockets or experimental procedures to measure their functional activity. However, progress in technologies relevant for drug

development such as structure-based drug design, proteolysis targeting chimeras (PROTACs) or hydrophobic tagging (HyT) (Bondeson et al., 2015; Burslem and Crews, 2020; Neklesa et al., 2011), however, have changed our concept of druggability (Gashaw et al., 2011; Hajduk et al., 2005) and increased the availability of difficult targets. PROTAC and HyT represent approaches that take advantage of the cellular protein destruction machinery and promote small-molecule-induced proteolysis of specific protein targets. PROTACs are bifunctional molecules that connect a ligand that binds to a protein of interest to an E3 ubiquitin ligase-recruiting ligand. Similarly, HyT is based on a target-specific ligand coupled to a hydrophobic moiety that mimics a partially unfolded protein and elicits an unfolded protein response to remove the target protein (Cromm and Crews, 2017). For both methods, ligands that specifically bind to the target protein are essential starting points for PROTAC and HyT based drug development. Therefore, recent progress in targeting technologies have rendered undruggable proteins into promising therapeutic targets to overcome drug resistance. In addition, we discuss immunogenic cell death as a strategy to eliminate therapy resistant cancer cells.

Small molecule therapeutics targeting transcription factors to eradicate drug resistant tumors

Cancer cells respond to drug treatment with the expression of genes that are involved in drug resistance. This transcriptional response is orchestrated by multiple transcription factors (Kohno et al., 2005). Most transcription factors were long time considered as “undruggable” targets (Bushweller, 2019). Transcription factors regulate gene expression programs involved in several diseases including cancer, neurodegenerative diseases, and diabetes. Indeed, transcription factors have been estimated to account for 20% of oncogenes in cancer (Vaquerizas et al., 2009). Targeting transcription factors has become an attractive strategy for the development of “personalized” therapy based on specific managing of the transcriptome. Transcription factors are activated or inhibited during several cancer treatments, leading inhibition of cancer cell growth or cell death, with significant impact on the therapeutic treatment. Current strategies to modulate the activity of transcription factors with small molecules or peptide-mimetics may be viewed as falling into four major strategies (Hagenbuchner and Ausserlechner, 2016): (1) inhibition of protein/protein interactions; (2) direct targeting of the binding of the transcription factor to DNA; (3) targeting chromatin remodeling/epigenetic reader proteins, and (4) blockage of protein/DNA-binding. Transcription factors may modulate gene transcription, either directly or indirectly, by forming complexes with identical or different transcription factor proteins: only these homo- or heterodimers can recognize the specific DNA sequences. Typical examples are the transcription factors p53 which associates with DNA as a tetramer, MYC/MAX dimers, STAT3 and HIF1. FOXO transcription factors may cooperate with SMAD, p53 or MYC and in part modulate target gene promoters that lack typical FOXO sites. These protein–protein interactions have attracted medicinal chemists on p53 as a target for the design of specific inhibitors (Stiewe and Haran, 2018; Cao, et al., 2020; Frezza and Martins, 2012).

The p53 tumor suppressor regulates the transcription of target genes, responds to DNA damage, leading to cell cycle arrest, apoptosis or senescence (Horn and Vousden, 2007) (Stiewe and Haran, 2018). p53 is frequently inactivated, due to mutations, in various cancers (Petitjean et al., 2007), and its reactivation has become a robust challenge in designing anticancer drugs (Martins et al., 2006; Vazquez et al., 2008) (Stiewe and Haran, 2018; Cao, et al., 2020; Frezza and Martins, 2012). Modulation of p53-mediated transcription (Yoon et al., 2002) depends on the abundance of p53 that correlates with the following biological outputs including apoptosis (Clarke et al., 1994). The tumor suppressor gene TP53 lies on the short arm of chromosome 17 (17p13.1) (Isobe et al., 1986). TP53 encodes for the p53 protein (43.7 kDa, 393 amino acids). The main role of p53 is to prevent alterations in the genome and to manage the expression of target genes; on the contrary, mutations in p53 play a key role in cancer formation

(Mantovani et al., 2019; Stiewe and Haran, 2018). Mutations in TP53 often reduce the expression of the p53 protein or may cause the production of inactive variants of p53, hence affecting its tumor suppressor activity. The antitumor agent doxorubicin (1) (Chart 1), a member of the anthracycline family, behaves as a topoisomerase II inhibitor, breaking the DNA at single or double strand level, thus interfering with DNA replication and transcription (Yang et al., 2014). The administration of doxorubicin would be responsible for the emergence of MDR due to loss of function p53 mutations and overexpression of MDR efflux pumps (Robey et al., 2018; Wijdeven et al., 2016). Drug resistance against doxorubicin and paclitaxel demonstrated that the cross-resistance between both drugs was induced by introduction of the p53 R248Q mutation in hepatocellular Hep3B cells. Such mutations could prompt the up-regulation of P-gp (ABCB1) expression (Chan and Lung, 2004). On the other hand, the p53 R273H mutation would be responsible for cross-resistance to doxorubicin and methotrexate by down-regulating procaspase-3 expression (Wong et al., 2007). Cisplatin (2) oxaliplatin and DACH-Pt the 3 platin derivatives, widely used as first line anticancer agents, are alkylating agents that interfere with DNA replication, linking primarily to guanine, causing apoptosis and failure of DNA repair (Chen and Chang, 2019). p53 plays a key role, managing multiple factors responsible for the development of cisplatin drug resistance. After an initial high response to platinum agents, the majority of cancer patients eventually exhibit the emergence of alterations in TP53 that is associated with the development of drug resistance (Chen and Chang, 2019; Singh et al., 2019). The nuclear transcription factor erythroid 2-related factor 2 (Nrf2) is downregulated by wild type p53 and upregulated by mutated p53 (Lisek et al., 2018). The expression by p53 of the apoptosis regulators BCL2, BCL2-like 1 (Bcl-XL), and hemeoxygenase 1 (HO-1), by regulating Nrf2, results in Nrf2-mediated resistance to cisplatin. This resistance could be reduced by BCL2 antagonists (Tung et al., 2015). The antimetabolite 5-fluorouracil (5-FU, 3) behaves as an inhibitor of thymidylate synthase, inducing cancer cell death by blocking dTMP biosynthesis. The intrinsic (primary) and acquired (secondary) resistance to 5-FU results from various mechanisms of drug resistance, including, among other, loss of function mutations in p53 (Deng et al., 2017; Marjaneh et al., 2019). Paclitaxel (4) is a first line anticancer agent which acts as a β -tubulin stabilizer causing the disruption of spindle formation and mitosis. Paclitaxel resistance of lung NSCLC cells developed upon over-activation of the p38 MAPK-EGFR signaling pathway, could be overcome by inhibiting the activity of p38 MAPK or EGFR through the induced degradation of MDM2 and consequent p53 stabilization (Park et al., 2016).

The transcription factor Nuclear Factor-kappa B (NF- κ B) is directly involved in innate and adaptive immune functions and plays as a key mediator of inflammatory responses. NF- κ B prompts the expression of several pro-inflammatory genes, including those encoding for cytokines and chemokines, and also participates in inflammasome regulation. Moreover, NF- κ B regulates the survival, activation and differentiation of innate immune cells and inflammatory T cells (Liu et al., 2017). Upon activation, the NF- κ B transcription factor translocates to the nucleus and initiates transcription of various genes including inflammatory cytokines or results in activation of cell apoptosis or necrosis pathways (Van Quickelberghe et al., 2018). Tumor Necrosis Factor (TNF) is a major inflammatory cytokine activating the transcription factor NF- κ B, but TNF is also able to induce apoptosis and necroptosis (Cabal-Hierro and Lazo, 2012; Wertz, 2014). TNF signaling is required to maintain tissue homeostasis and prevents inflammatory pathology (Brenner et al., 2015). Most inflammatory effects of TNF are mediated through the TNF Receptor 1 (TNFR1), and inhibition of TNFR1-NF- κ B signaling pathway, as seen with TNF antagonists, possesses beneficial effects in autoimmune and inflammatory syndromes (Puimège et al., 2014; Varfolomeev and Vucic, 2018; Workman and Habelhah, 2013).




Chart 1. Chemical structures of p53 (1-4) and NF- κ B modulators (5-7).

TNF is expressed as a transmembrane protein (memTNF) that can be processed into a soluble form (sTNF) (Locksley et al., 2001). Protein-protein interactions of the sTNF/TNFR1 type are typically considered undruggable not only because of the high affinity of the protein pairs, but also because of the perception that only a broad distribution of poorly contoured interactions exists across the binding partners (Lang et al., 2016; Xu et al., 2017). Thanks to recent developments in modern drug discovery, an increasing number of crystal structures and homology models are available, thereby allowing application of computational tools to quantify protein interfaces (Tian et al., 2018). The introduction of small molecules to influence the protein-protein interaction of TNF- α with its receptor has been reviewed (Richmond et al., 2015; Song and Buchwald, 2015). Resistance to drugs that target DNA derives from DNA-repair proteins as a result of NO nitrosation and denaturation of several proteins by NO that are involved in DNA repair, leading to an enhanced drug cytotoxicity (Kim et al., 2017). Furthermore, NO also regulates the chemosensitivity of cancer cells by nitrosylating, and therefore inhibiting, the NF- κ B pathway (Huerta-Yepez et al., 2013). Several studies performed on a variety of MDR cell lines showed that high NO levels can overcome drug resistance. For example, NO was capable of reversing cisplatin resistance in tumor cells as the downregulation of NF- κ B/Snail/YY1/ RKIP circuitry after epithelial-to-mesenchymal transition (Bonavida et al., 2008; Bonavida and Baritaki, 2011; Wottrich, et al., 2017; Hays and Bonavida, 2019). The inducible nitric oxide synthase (iNOS) produces endogenous NO that may also reverse the MDR phenotype. Silencing RhoA, a small GTPase of the Rho family, activates the NF- κ B pathway and iNOS activity; the consequent accumulation of doxorubicin in both HT29 and HT29-dx colon cancer cells leads to the surmounting of drug resistance (De Boo et al., 2009).

The repurposing of drugs has been applied in several chemotherapeutic strategies to treat human health disorders such as cancer (Antoszczak et al., 2020; Armando et al., 2020; Dinić, et al., 2020; Kopecka, et al., 2020; Mudduluru, 2016). The antiparasitic drug niclosamide (5) was shown to act as a multitargeted drug against both cancer cells and cancer stem cells (CSCs). Niclosamide inhibited the Wnt/ β -catenin, mTORC1, STAT3, NF- κ B, NFAT and Notch signaling pathways, targeting glutathione biosynthesis and mitochondria in cancer cells and, thereby induced cell growth inhibition and apoptosis (Hamdoun et al., 2017; Li et al., 2014).

The antitumor activity of thalidomide (**6**) was initially attributed to its potential antiangiogenic effects through the inhibition of both basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) (D'Amato et al., 1994). Further evidence demonstrated that thalidomide also suppressed the production/expression of proangiogenic factors, such as TNF- α , NF- κ B, IGF-1, IL-6, IL-8, PGE2, chemokine receptor type 4 (CXCR4) and stromal cell-derived factor-1 (SDF-1) (Bouyssou et al., 2016). Thalidomide displays immunomodulatory and anti-inflammatory activity due to its capability to modulate the production and activity of several cytokines, including interleukins IL-6, IL-10, IL-12, IL-1 β , and TNF- α . It was demonstrated that thalidomide downregulates NF κ B, a key transcription factor for TNF and other cytokines, by suppressing the activity of I κ B kinase (Keifer et al., 2001). These modulatory effects affect the antiangiogenic and anti-proliferative effects of thalidomide.

Antidiabetic drugs have also been investigated for potential anti-cancer activity (Klii-Drori et al., 2017). The effect on MDR mediated by the diabetic drug metformin (**7**), was attributed to the modulation of ATM/LKB1/AMPK signaling, which regulates downstream proteins, such as mTOR, MAPKs and transcription factors including NF- κ B, FOXO and p53 (Kamarudin et al., 2019). The anti-cancer properties of metformin rely on its capacity to decrease ATP production and modulate mitochondrial activity (Saraei et al., 2019; Vial et al., 2019). In mouse models of triple-negative breast cancer (TNBC), metformin inhibits CSCs (Hirsch et al., 2009). Metformin is capable to reverse the MDR phenotype in a variety of cancer models. Metformin decreased the DOX-induced expression of P-gp/MDR1/ABCB1 and HIF-1 α in MCF7-DOX breast cancer cells and, similarly, in a breast cancer xenograft model derived from a patient tumor (Davies et al., 2017). In a model of drug resistant MCF7-FU cells, metformin reversed MDR through AMPK pathway activation and inhibition of EMT (Qu et al., 2014). Drug combination of DOX and metformin co-encapsulated in nanoparticles showed increased accumulation of DOX and cytotoxicity in MCF-7 cells which was superior to the free drug combination (Shafiei-rannejad et al., 2018).

HIF is an oxygen-sensitive transcription factor that plays a key role in adaptation of cells to oxygen stress by regulating transcriptional programs involving cell viability, metabolism, proliferation, and angiogenesis (Olenyuk et al., 2004). Orchestration of these key programs generally results in human diseases such as cancer, anemia, ischemia and hypoxic-ischemic diseases (Higashijima et al., 2013; Jain et al., 2018). Overexpression of the HIF pathway has been correlated to invasive cancer and resistance to radiation in patients with advanced tumors (Masoud and Li, 2015). On the other hand, hypoxia and HIF pathway have been correlated to a large proportion in solid tumors (Warfel and El-Deiry, 2014). Small molecules interfering with the HIF pathway have become a promising approach to treat a variety of solid tumors, such as breast cancer, lung cancer, multiple myeloma, and renal cell carcinoma. Such compounds may include degradation promoters of the HIF-1 α protein, disrupters of the HIF- α /HIF- β interaction, and, most importantly, blockers of the HIF- α /p300 interaction (Li et al., 2019; Wei et al., 2018). Distal hypoxia response elements (HREs) regulate HIF target genes such as erythropoietin (Orlando, et al., 2020). HIF consists of two subunits: HIF- α , made by three isoforms, HIF-1 α , HIF-2 α , and HIF-3 α (Ema et al., 1997; Gu et al., 1998) is regulated by oxygen, as well as HIF- β (only one subtype) that is constitutively expressed. HIF-1, consisting of HIF-1 α and HIF- β subunits, is the most extensively investigated HIF isoform (Li et al., 2019). HIF-1 α overexpression in cancer progression has been correlated with NF- κ B pathway, accumulation of p53 (Sang et al., 2002), and recruitment of the transcriptional HIF-1 co-activator p300 (Semenza, 2002). Inhibition of HIF-1 and inhibition of HIF-2 are the principal reported strategies to down-regulate the HIF pathway. LW6 (**8**, Chart 2) (Boovanahalli et al., 2007) and PX-478 (**9**) (Schwartz et al., 2010) behave as indirect regulators through suppression of hypoxia-induced transcriptional activity and modulate of HIF- α translation and stabilization leading to a reduction in HIF protein levels. In search for selective HIF-1 α inhibitors focused

on the protein-protein interaction between HIF-1 α C-terminal transactivation domain (C-TAD) and the co-transcription factor p300/coactivator protein CBP (Arany et al., 1996; Hay et al., 2014). Chetomin (**10**) (Kung et al., 2004) and the KCN1 derivative **11** (Yin et al., 2012) exert direct inhibition of the HIF-1 α /p300 interaction with no apparent effect on the intracellular levels of HIF-1 α . Both **10** and **11** showed little toxicity *in vivo*, indicating that they have potential as drugs for the treatment of vascular disease and cancers. The development of selective HIF-1 α and HIF-2 α inhibitors was hampered by the fact that these subtypes share 48% amino acid homology. The potent and selective HIF-2 α inhibitor PT2385 (**12**) showed appreciable activity in phase I clinical studies, paving the way for the development of a new class of HIF-2 α -specific inhibitors (Wehn et al., 2018).

The Wnt signaling pathway is one of the major signaling mechanisms regulating tissue homeostasis and has been found to be deregulated in a variety of human diseases. Nuclear DNA-binding TCF/LEF proteins and their transcriptional co-activator β -catenin represent key components of the canonical Wnt signaling pathway (Hrckulak et al., 2016). In the absence of Wnt ligand, β -catenin is phosphorylated in the cytoplasm through the destruction complex, and then ubiquitinated by β -transducing repeats-containing proteins (β -TrCP) and degraded by the proteasome or, alternatively, phosphorylated by the destruction complex and followed by β -TrCP ubiquitination. In the presence of a Wnt ligand, after interaction with frizzled receptor, β -catenin translocates into the nucleus, where it activates the expression of TCF/LEF target genes (Clevers et al., 2014; Clevers and Nusse, 2012). The aberrant deregulation of β -catenin in tumor cells boosts the transcription of many oncogenes, resulting in the development of various cancers, such as colon cancer, hepatocellular carcinoma, pancreatic cancer, lung cancer and ovarian cancer (Shang et al., 2017). Anticancer drugs that interfere with the Wnt/ β -catenin signaling pathway have not been approved so far. Known inhibitors targeting Wnt ligand, its receptor, β -catenin subcellular localization or β -catenin transcriptional complex are viewed as falling into five main classes: small molecules, peptides, antibodies, RNA interference and natural compounds (Shang et al., 2017).




Chart 2. Chemical structures of HIF modulators (**8-12**).

LGK974 (**13**) (Chart 3) is a potent small-molecule Wnt ligand and receptor inhibitor of membrane-bound *o*-acyltransferases-porcupine (PORCN) that showed efficacy in multiple tumor models, such as murine breast cancer and human head and neck squamous cell carcinoma *in vivo* (Liu et al., 2013). Some antibodies targeting Wnt ligands, such as OMP-18R5, OTSA-101 and OMP-54F28, have been selected for clinical trials (Sebio et al., 2014). G007-LK (**14**) and JW55 (**15**) are tankyrase 1/2 inhibitors (Huang et al., 2009) in preclinical research which show stabilizer activity on Axin2, thus causing an increase of β -catenin degradation (Lau et al., 2013; Waaler et al., 2012). Pyvinium (**16**) is a small molecule that activates the phosphorylation of β -catenin by casein kinase 1 (CK1) to

promote its degradation (Thorne et al., 2010). The non-steroidal anti-inflammatory drug (NSAID) celecoxib (**17**) reduces the auto-phosphorylation of c-Met, a tyrosine kinase receptor, resulting in GSK3 β activation and β -catenin degradation (Tuyman et al., 2008). The phytoestrogen genistein (**18**) was found to promote β -catenin degradation through activation of GSK3 β (Su and Simmen, 2009). Small peptide derivatives proved to hamper the protein-protein interaction of β -catenin with specific import chaperones in some tumor types, i.e., by disruption of the BCL9/ β -catenin complex, resulting in reduced accumulation of β -catenin in the nucleus and suppression of its transcriptional activity (Takada et al., 2012). ICG-001 (**19**) is a small molecule targeting β -catenin-cyclic AMP response element-binding protein (CBP) (but not β -catenin-p300) capable of downregulating the expression of β -catenin-TCF-responsive genes (Emami et al., 2004). TSAH-BCL9 (**19**) is an α helix stabilizer that disassembles native β -catenin-BCL9 complexes and selectively suppresses Wnt transcription, leading to an antitumor effect (Takada et al., 2012, p. 9). Ethyl 4-((4-(trifluoromethyl)phenyl)sulfonamido)benzoate (compound **20**) inhibits the effect on Wnt reporter with an IC₅₀ value of 7.0 μ M, significantly reduces c-MYC levels, inhibits HCT116 colon cancer cell growth (IC₅₀ = 20.2 μ M), does not violate Lipinski and Veber rules, and shows predicted Caco-2 and MDCK cell permeability Papp>500 nms⁻¹ (Di Magno et al., 2020). Transcription factors belonging to the Gli family contain DNA binding zinc finger domains and represent the transcriptional effectors of Hedgehog (Hh) signaling pathway. Constitutive activation of Hh has been shown in several cancer types and is a driver of chemoresistance (Scales and de Sauvage, 2009). Major progress has been made in the development of Hh pathway inhibitors for the treatment of patients with cancer (Amakye, et al., 2013). In particular, Infante et al. identified Glabrescione B as the first small molecule binding to Gli1 zinc finger and impairing Gli1 activity by interfering with its interaction with DNA (Infante, et al., 2015).

Wnt/ β -catenin modulators




Chart 3. Chemical structures of Wnt/ β -catenin modulators (13-20).

FOXO proteins are transcription factors that are involved in numerous physiological processes and in various pathological conditions, including cardiovascular disease, cancer, diabetes and chronic neurological diseases (Calissi et al., 2021). FOXO transcription factors bind to the promoter regions of a wide range of target genes (Link and Fernandez-Marcos, 2017) and play a key role in the regulation of cellular homeostasis. Their activity is regulated through post-translational modifications (PTMs) such as phosphorylation, acetylation, ubiquitylation and methylation (Eijkelenboom and Burgering, 2013; van der Horst and Burgering, 2007). The PI3K/AKT signaling pathway represents the major inhibitory input to FOXO activity, while FOXO proteins are activated by cellular stress signaling (Brown and Webb, 2018). FOXO

proteins have emerged as longevity genes, in particular FOXO3 (Martins et al., 2016), and are known to be involved in senescence, autophagy, stem cell maintenance and ageing (Calissi et al., 2021 and references therein). FOXO proteins can behave as tumor suppressors and frequently get inactivated in several human tumors (Dansen and Burgering, 2008; Paik et al., 2007). Enzymes regulate FOXO activity mostly via post-translational modifications (PTMs). These findings raise the possibilities to modulate FOXO activity as an ideal target to achieve a therapeutic benefit. Large screening programs have been conducted in search for FOXO targeting small molecules to treat several human diseases. Several compounds from different sources, including natural products, synthetic and semi-synthetic or drugs already in use have been evaluated for their capacity to modulate FOXO activities. Such compounds may either maintain, stimulate or inhibit FOXO activity (Hornsveld et al., 2018).

Selinexor (KPT-330, **21**, Chart 4) is a karyopherin chromosome region maintenance-1 (CRM1, also termed XPO1) inhibitor and has been approved for its clinical use to treat patients with multiple myeloma (Ferreira et al., 2020a, p. 1). CRM1 participates in the nuclear export of FOXO1, which finely modulates the effect of **21** and marginally of the combination with cisplatin (Gounder et al., 2016). These findings provide preclinical evidence of potential clinical impact on ovarian carcinoma and highlight the interest in **21**-based combination therapies designed to enhance the cell death of tumor cells. Likely, given the role of CRM1 in the localization of cellular proteins, it could affect the cellular response of ovarian cancer cells to cisplatin and its combination with **21** (Corno et al., 2018).

ETP-45658 (**22**), dactolisib (NVP-BE235, **23**) and capivasertib (AZD5363, **24**) increase nuclear localization of FOXO3. Compound **22** is a potent and selective inhibitor of phosphoinositide 3-kinases synthesized after computational and structure-activity relationship studies of a pyrazolopyrimidine scaffold that demonstrated a desired mechanism of action in tumor cell lines and *in vivo* in treated mice (Link et al., 2009). The phosphoinositide 3-kinase (PI3K)/AKT pathway is activated in a variety of solid and non-solid tumors (Vivanco and Sawyers, 2002). Such activation is frequently mediated by mutations in PI3K α with enhanced production of phosphatidyl 3,4,5-trisphosphate (PIP3) (Zhao and Vogt, 2008), or by mutations/deletions in the tumor suppressor phosphatase and tensin homolog (PTEN). The activated form of AKT phosphorylates several effector molecules including the FOXO transcription factors (Burgering, 2008; Calnan and Brunet, 2008). Upon cell treatment, compound **22** decreased the phosphorylation of AKT at Ser473, of FOXO at Thr32 and of p70S6K at Thr389 in cells after treatment with the compound. It induced the nuclear translocation of FOXO tagged with green fluorescent protein (GFP) with an EC₅₀ value of 45 nM, and, consistently, inhibited the PI3K with an IC₅₀ of 22 nM. Compound **22** showed anti-proliferative activity in a variety of tumor-derived cell lines, and this activity appeared to be independent on the PI3K α and PTEN mutational status (Link et al., 2009). Compound **23** is a dual inhibitor of the PI3K and downstream mammalian target of rapamycin (mTOR) that inhibits the activation of the downstream effectors AKT, S6 ribosomal protein, and 4EBP1 in breast cancer cells. Compound **23** inhibited the PI3K/mTOR axis and results in anti-proliferative and antitumor activity in cancer cells with both wild-type and mutated p110- α (Serra et al., 2008). Compound **24** is a potent inhibitor of AKT. Tumor types with PIK3CA mutation, PTEN mutation, or HER2 gene amplification, without coincident RAS mutation, exhibit the highest frequency of response to **24** *in vitro*. Compound **24** has also the potential to overcome resistance or increase the sensitivity to HER2 inhibitors in breast cancer, and greatly sensitizes to docetaxel chemotherapy, resulting in tumor regression *in vivo* (Davies et al., 2012). Very recently, health-promoting compounds have been assessed for their capacity to induce the activity of FOXO3 and the natural occurring alkaloids harmine and piperlongumine were identified as potent activators of FOXO3 nuclear localization (Jimenez, et al., 2021).

Several other compounds have been reported to interfere with FOXO activity. For example, tanzawanic acid D (**25**) behaves as a stabilizer of FOXO1 binding to DNA; AS1842856 (**26**) reduced FOXO1 activity by binding directly to the protein; carbenoxolone repressed FOXO3 activity by binding to the FOXO3 DNA binding domain; the proteasome inhibitor bortezomib (velcade) behaves as a FOXO stabilizer. Therefore, modulation of FOXO proteins through the design and synthesis of targeted small molecules appears as an attractive approach towards the development of targeted anticancer drugs (Link et al., 2009).




Chart 4. Chemical structures of FOXO modulators (**21-26**).

Pseudokinases, an emerging group of druggable targets

There is growing evidence that several kinases possess non-catalytic functions in addition to their catalytic role (Jacobsen and Murphy, 2017; Kung and Jura, 2019, 2016; Shaw et al., 2014). It was predicted from analysis of the human genome that about 10% of all protein kinases do not play catalytic activity and that they play a role in signaling pathway through different mechanisms (Manning et al., 2002). These kinases bear mutations that render their catalytic site inactive. This family of kinases are called pseudokinases (Kung and Jura, 2019), and, similarly to the other kinases, play key roles in cellular function and signaling, and are found often altered in several diseases (Boudeau et al., 2006; Reiterer et al., 2014).

Most importantly, the nucleotide binding site of pseudokinases was shown to host small molecules with drug-like properties, thus making it an attractive target for drug design (Kung and Jura, 2016). Moreover, several pseudokinases are unable to bind a nucleotide, and lack a binding site for small molecules that are competitive with the ATP (Kung and Jura, 2016). Murphy and co-workers identified four classes of pseudokinases: class 1 of pseudokinases lack the ability to bind traditional ligands, such as nucleotides and metal cations, in their pseudoactive sites (Murphy et al., 2014); class 2 pseudokinases bind nucleotides in the absence of cations, such as Mg^{2+} that enables nucleotide binding to the kinase active site, and are required for ATP coordination and transfer of the phosphate groups (Zheng et al., 1993); several pseudokinases of this group are able to bind to ATP even in the absence of cations, meanwhile the binding to the nucleotide binding site is inhibited in the presence of Mg^{2+} (Bailey et al., 2015; Cui et al., 2017); class 3 pseudokinases bind divalent cations but not nucleotides or ATP-competitive small molecules (Murphy et al., 2014); class 4 include pseudokinases able to bind both nucleotides and divalent cations. These pseudokinases show detectable catalytic activity, but to a lesser extent compared to the fully active kinases (Jura et al., 2009).

TX1-85-1 is a selective Her3 ligand that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. Her3 is recognized as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules due to the lack of significant kinase activity. Compound TX1-85-1

was manipulated by introducing an adamantane moiety to generate the bivalent ligand TX2-121-1 (**27**, Chart 5). Treatment of cells with TX2-121-1 induced partial degradation of Her3 and interfered with heterodimerization between Her3 with either Her2 or c-Met (Xie et al., 2014). Lapatinib (**28**) is an ATP-competitive inhibitor of HER2 that is able to induce cell proliferation cooperatively with the HER3 ligand neuregulin by promoting atypical HER2-HER3 heterodimerization.

Pseudokinase modulators

HER3





Chart 5. Chemical structures of HER modulators (**29-31**).

Compound **28** drives the formation of the HER2-HER3 complex by stabilizing a particular HER2 conformer. Formation of these dimers activates a proliferative outcome as a response to neuregulin (Claus et al., 2018). CT8 (**29**) binds the Sec61 transposon thus preventing the initial translational translocation of the nascent HER3 protein. As a result, HER3 but none of the other HER proteins is degraded. Treatment with **29** suppresses the induction of HER3 during lapatinib treatment in cancers with HER2 gene amplification and increases the apoptotic effects of lapatinib (Ruiz-Saenz et al., 2015).

Kinase suppressor of Ras (KSR), a Ras-mitogen activated protein kinase (MAPK) scaffold that is an early event in many different cancers and a key driver of resistance to targeted therapies, may be allosterically modulated through dimerization with RAF proto-oncogene serine/threonine-protein kinase (RAF). Based on mutations that selectively suppress oncogenic Ras signaling, Dhawan and co-workers developed a class of KSR stabilizers, APS-2-79 (**30**, Chart 6). This compound was able to modulate KSR-dependent MAPK signaling by antagonizing RAF heterodimerization as well as the conformational changes required for phosphorylation and activation of KSR-bound mitogen-activated protein kinase (MEK), and to increase the potency of several MEK inhibitors specifically within Ras-mutant cell lines by antagonizing the release of negative feedback signaling (Dhawan et al., 2016).




Chart 6. Chemical structures of KSR2 (**30**), MLKL (**31,32**), RNase L (**33**) and TRIB2 (**34**) modulators.

ASC24 is a KSR2 inhibitor that, presumably, causes a conformational change in KSR2, mimicking the binding to KSR Arg718 by BRAF. MEK1 alteration leads to its increased phosphorylation consistently with its capacity to disrupt the KSR2(KD) homodimer interface. Thus, a KSR–MEK complex inhibitor and BRAF antagonist could behave analogously to the Ras suppressor: the KSR(R718H) mutation (Brennan et al., 2011; Statsuk et al., 2008). Hildebrand and co-workers showed that the MLKL pseudokinase domain acts as a latch to restrain the N-terminal four-helix bundle (4HB) domain and that unleashing this domain results in formation of a high-molecular-weight, membrane-localized complex and cell death. Cpd 1 (GW806742X, **31**) was reported as a type II kinase inhibitor that reportedly binds to the MLKL pseudokinase domain and prevents necroptosis (Hildebrand et al., 2014). Ma and co-workers measured protein conformational changes using second harmonic generation (SHG) to confirm that **31** is a non-selective type II inhibitor that also inhibits the upstream kinase RIPK1 (Ma et al., 2016). The R-enantiomer cpd 4 (**32**) was found to bind selectively to MLKL with $KD = 230$ nM without binding RIPK1 or RIPK3; its S-enantiomer showed a weaker binding to MLKL with $KD = 7600$ nM. In contrast to Hildebrand and co-workers (Hildebrand et al., 2014), these studies indicated that an ATP-pocket inhibitor of the MLKL pseudokinase domain does not have any impact on the necroptosis pathway. Neither the MLKL selective analog **32** (R-enantiomer) nor the truncated versions of **31** with better selectivity against RIPK1 rescued cells from necroptosis (Ma et al., 2016).

The anti VEGF and PDGF ATP-competitive agent sunitinib (**33**) inhibited both RNase L and PKR with IC_{50} values of 1.4 and 0.3 μ M, respectively. It had no effect on encephalomyocarditis virus growth in cells lacking both PKR and RNase L. Also, **33** reduced mean survival times from 12 to 6 days in virus-infected WT mice while having no effect on survival of mice lacking both RNase L and PKR (Jha et al., 2011).

Tribbles 2 (TRIB2) is a cancer-associated pseudokinase with a diverse interactome, includes MEK1 and AKT as binding partners. There is substantial evidence that human TRIB2 promotes survival and drug resistance in solid tumors (Ferreira et al., 2021; Mayoral-Varo et al., 2021) and hematological cancers (Stein et al., 2015) and therefore is of interest as a therapeutic target. The TRIB2 destabilizing agent afatinib (**34**) caused rapid TRIB2 degradation in human AML cancer cells (Foulkes et al., 2018) providing the proof of concept for the druggability of the TRIB2 oncoprotein. In addition, harmine and piperlongumine have been shown to induce inverse matched signatures compared to TRIB2-mediated transcriptional signatures as determined by connectivity map-based analysis (Machado, et al., 2020). These data together with the FOXO3 activating effect of both

alkaloid compounds mentioned above are in line with the role of TRIB2 as a FOXO repressor protein (Zanella, et al., 2010)

Targeting the nuclear export receptor CRM1

Chromosome region maintenance 1 (CRM1, also reported as XPO1 or exportin 1) is an export protein of the karyopherin- β family of transport receptors that mediates the nuclear exports of proteins that contain leucine-rich nuclear export signal (NES) (Ferreira et al., 2020b; Fornerod et al., 1997; Fukuda et al., 1997). CRM1 is involved in the nuclear export of several proteins with tumor suppressor and oncogenic activity, for example retinoblastoma, APC, FOXO proteins, INI1/hSNF5, galectin-3, Bok, NPM1, RASSF2, Merlin, p53, p21CIP1, p27KIP1, N-WASP/FAK, estradiol receptor, Tob, BRCA1, BCR–ABL and eIF4E. Worthy to note, such proteins appear to be spread inside the tumor cells (Hill et al., 2014). In a wide variety of both solid and blood tumor types the expression of CRM1 was found to be remarkably increased (Gao et al., 2015; Inoue et al., 2013; Kojima et al., 2013; Lalapombella et al., 2012; Noske et al., 2008; Schmidt et al., 2013, p. 1; Shen et al., 2009; Tai et al., 2014; van der Watt et al., 2014, 2009, p. 1; Yao et al., 2009, 2009; Yoshimura et al., 2014; Zheng et al., 2014; Zhou et al., 2013). Accordingly, the expression of high level of CRM1 correlates with size and spread of distant metastasis of the tumor (Turner et al., 2012; Turner and Sullivan, 2008). Due to the crucial regulatory role and the alteration in human cancer, CRM1 has emerged as a therapeutic target for anticancer therapy. Several nuclear export inhibitors (NEIs) have proven to sensitize drug-resistant cancer cells to anti-cancer treatments (Ferreira et al., 2020c, p. 1). They are natural products and synthetic; natural product NEIs are derived from bacterial, plant, fungal or animal sources (Sun et al., 2016).

Leptomycin B (LMB, elactocin, **35**, Chart 7) is a natural product isolated from *Streptomyces spp* originally discovered as an antifungal agent (Hamamoto et al., 1983). LMB was identified as a CRM1 inhibitor by Kudo (Kudo et al., 1998). Compound **35** forms a covalent bond with Cys528 of the human CRM1 in the NES-binding groove through a reaction type Michael addition involving its 5,6-dihydro-2H-pyran-2-one moiety (Dickmanns et al., 2015; Kudo et al., 1999). The covalent bond with Cys528 inhibits the formation of the NES-CRM1-RanGTP complex and thereby the export of the cargo protein to the cytoplasm. In clinical trial, compound **40** showed systemic toxicity, despite its appreciable anticancer activity, possibly due to a permanent block of nuclear export of essential macromolecules (Newlands et al., 1996). Some analogs of **35**, the Anguinomycins isolated from *Streptomyces sp. Ratjadone*, form a covalent bond with Cys238, show EC_{50} values at nanomolar concentrations, and are also highly cytotoxic (Sun et al., 2013, p. 1).

1'S-1'-acetoxychavicol (galangal) acetate (**36**) was isolated from the rhizomes of *Alpinia galanga*. Compound **36** inhibited Rev transport at a low concentration by binding to CRM 1 and accumulating full-length HIV-1 RNA in the nucleus, resulting in a block in HIV-1 replication in peripheral blood mononuclear cells (Ye and Li, 2006).

Valtrate (**37**) was obtained after separation of the extract of *Valeriana Radix*, and it was shown to inhibit the export from the nucleus to cytoplasm of the *Schizosaccaromyces pombe* fused protein at 3 μ g/mL (Murakami et al., 2002). To compare the mode of action of **37** and callystatin (**38**) a polyketide isolated from a marine sponge by the same group, the authors considered the simplified compound **39**, a Rev-transport inhibitor with a MIC of 3.8 μ M.

Compound **37** was presumed to inhibit Rev transport from the nucleus to cytoplasm through direct binding to the Cys-529 in CRM1. In order to compare the modes of action between **37** and **38**, a biotinylated probe was synthesized. The analysis of the binding protein demonstrated that both **37** and **38** inhibit Rev-transport in the same fashion (Murakami et al., 2002).

Watanabe and colleagues examined CRM1 inhibitors, and found that both **36** and **37** are potent inhibitors of influenza virus replication (Watanabe et al., 2011).

CRM1 inhibitors




Chart 7. Chemical structures of CRM1 inhibitors (35-41).

Piperlongumine (**40**) is a natural alkaloid of *Piper longum* endowed with anti-microbial, anti-inflammatory and platelet aggregation inhibitory properties (Adams et al., 2012). Niu reported that compound **40** may behave as nuclear export inhibitor though retention of tumor suppressor proteins and inhibition of the interactions between CRM1 and these proteins. It could directly bind to the conserved Cys528 of CRM1; notably, cancer cells expressing the CRM1 C528S mutation are resistant to **40** (Niu et al., 2015b).

Plumbagin (**41**) is a naphthoquinone derivative extracted from the plant *Plumbago zeylanica* endowed with anti-proliferative activity in both cellular and animal models. Liu reported that cells incubated with **41** accumulated tumor-suppressor proteins in the nuclei and hampered the interaction of these proteins with CRM1. Consistent with the weaker cytotoxicity, **41** suppressed the nuclear export at higher concentrations than **35**. Compound **41** binds directly to the conserved Cys528 of CRM1, like **35**, but not to the Cys528 mutated peptide. In this respect, cells bearing the CRM1 C528S mutation were resistant to **41**. Nuclear retention of FOXO1 could be observed in the presence of **35** or **41**; in contrast, cytoplasmic FOXO1 was observed only in CRM1-Cys528 mutant cells (Liu et al., 2014).

In search for new Rev inhibitors of HIV, Daelemans identified a new small molecule antiviral agent, PKF050-638 (**42**, Chart 8) that behaves as an inhibitor of the CRM1-mediated Rev nuclear export and inhibits in a dose-dependent manner Rev-dependent mRNA expression in a cellular assay for Rev function. The authors demonstrated that **42** disrupts CRM1-NES interaction using a quantitative *in vitro* CRM1-nuclear export signal cargo-binding assay and reversibly interferes with the colocalization of CRM1 and Rev in the nucleolus. Similarly to **35**, the mode of action of **42** is through a direct and reversible interaction with Cys539 (Daelemans et al., 2002). Sakakibara reported that CBS9106 (**43**) is an inhibitor of CRM1-dependent nuclear export that causes cell cycle arrest and induces apoptosis in a broad spectrum of cancer cells, including multiple myeloma. Compound **43** leads to a significant reduction of CRM1 protein levels without any apparent effect on CRM1 mRNA expression. After oral administration, compound **43** suppressed significantly tumor growth and prolonged survival in mice bearing human tumor xenografts (Sakakibara et al., 2011).

Kau performed a phenotypic screen in order to identify small molecule inhibitors of nuclear export of the transcription factor FOXO1a. The study led to the identification of 19 novel

compounds that promote retention of FOXO1a in the nucleus. These molecules block the nuclear export of RevGFP and FOXO1a by selective targeting CRM1. Of the 19 compounds in this class, 5219668 (**44**) was the most potent CRM1 inhibitor, although less potent than compound **35** (Kau et al., 2003). Similarly, Cautain et al., performed a high content screening of 14,000 different microbial extracts, purified the fungal metabolite MDN-0105 and characterized it as a potent CRM-1 inhibitor capable of inducing FOXO3 and NFκB2 nuclear translocation (Cautain et al., 2014).

Niu investigated S109 (**45**), a novel reversible CRM1 inhibitor in colorectal cancer cells that inhibited cell proliferation and induced cell cycle arrest. Compound **45** has shown nuclear retention of major tumor suppressor proteins. The reduction of CRM1 protein level was likely mediated through a reversible mechanism involving the proteasome pathway. The Cys528 mutation of CRM1 prevented the ability of **45** to block nuclear export (Niu et al., 2015a, p. 1).

Selective Inhibitors of Nuclear Export (SINEs) are characterized by slow and reversible binding. The Cys528 mutation confers resistance to SINE compounds, meanwhile the E571K mutation does not induce resistance via CRM1-mediated nuclear export (García-Santisteban et al., 2016). The CRM1 antagonist, selinexor (KPT-330, **21**, see also above) promoted rapid apoptosis at low nanomolar concentrations in a panel of human T-cell acute lymphoblastic leukemia (T-ALL) cell lines, and arrested cell cycle in the G1 phase. Compound **21** demonstrated prominent growth suppression *in vivo* of T-ALL cells and demonstrated high activity against acute myeloid leukemia (AML) cells, with little toxicity to normal murine hematopoietic cells (Etchin et al., 2013).

Verdinexor (KPT-335, **46**) is an orally bioavailable, selective CRM1 inhibitor. Compound **46** is being evaluated in a variety of viral indications as well as autoimmune and inflammatory diseases. Compound **46** inhibited CRM1-mediated transport and reduced respiratory syncytial virus (RSV) replication *in vitro*. It proved to be effective against both strains A and B of RSV and reduced viral replication following prophylactic or therapeutic administration. The mechanism of inhibition was through a combined effect of reduced CRM1 expression, disruption of the nuclear export of RSV M protein, and inactivation of the NF-κB signaling pathway (Jorquera et al., 2019). It has the potential to treat viral diseases through inhibition of viral replication and suppression of inflammatory cytokine-mediated symptoms.


Eltanexor (Z-isomer, KPT-8602, **47**) showed an improved tolerability profile compared to compound **21** due to its reduced brain penetration, with attenuation of the central nervous system mediated side effects of anorexia and weight loss. Compound **47** showed promising anticancer activity in preclinical models of colorectal cancer (CRC). It exhibited antileukemic efficacy against leukemic blasts and leukemia initiating cells (LICs) in AML patient-derived xenograft models. Importantly, normal hematopoietic stem and progenitor cell frequency is not significantly reduced by **47**, providing a therapeutic window for the elimination of relapse-driving LICs while sparing normal HSPCs (Etchin et al., 2017). Compound **47** displayed a strong synergism with dexamethasone on human B-ALL and T-ALL cell lines as well as *in vivo* in three patient-derived ALL xenografts (Verbeke et al., 2020).

The treatment of tumors with mutations in the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKIs) represents one of the major breakthroughs in lung cancer management. The acquired T790M mutation accounts for the majority of resistance cases.

In addition to the acquired T790M mutation, the resistant PC9GR cells had very different transcription programs from the sensitive PC9 cells. KPT-185 (**48**) suppressed growth, caused apoptosis, and inhibited migration of the PC9GR cells at similar (or better) rates as the sensitive PC9 cells in a dose-dependent manner (Wei et al., 2020). Both compounds **48** and **49** (KPT-276) were investigated for the antileukemic activity *in vitro* and *in vivo* in AML. Compound **48** displayed potent anti-proliferative activity with IC₅₀ values of 100-500 nM, induced apoptosis, cell cycle arrest, and myeloid differentiation in AML cell lines and patient blasts. In a FLT3-ITD-positive MV4-11

xenograft murine model, compound **49** significantly prolonged survival of leukemic mice (Ranganathan et al., 2012).

CRM1 inhibitors - 2nd generation



SINEs




Chart 8. Chemical structures of CRM1 inhibitors (2nd generation) (42-45) and SINEs (46-49).

It is important to note that apart from CRM-1, there is a broad range of nuclear import and export receptors with different affinities to cellular substrates involved in cancer progression and therapy resistance and that most of these potential targets are completely unexplored (Hill et al., 2014).

Immunogenic cell death strategy

Cancer immunotherapy has recently emerged as an important alternative strategy to treat MDR positive cancers by leveraging the cytotoxic potential of the human immune system.—Indeed, multiple factors can be related to immunotherapy resistance as characteristics of the tumor microenvironment (TME), presence of tumor infiltrating lymphocytes (TILs) such as CD8⁺ T lymphocytes associated with treatment-response, or presence of tumor associated macrophages (TAMs). In addition, the activation of a number of regulators and the presence of other specific molecules or cells has also been described (Pérez-Ruiz et al., 2020). On their side, MDR cells are characterized by a high immune-evasive capacity since they have poor immune-activating molecules on their surface. They can also produce immunosuppressive metabolites that do not allow the host immune system to mount an anti-tumor response. The main reason for chemo-immune-resistance of MDR cancer cells is due to their ability to adapt to stressors, this phenotype being part of a multi-stress resistance phenotype. In this respect, one strategy to overcome MDR could consist of restoring oxidative stress sensitivity of MDR cells (Riganti and Contino, 2019). Indeed, ROS play a central role in cancer cells by regulating

and inducing apoptosis, thereby modulating cancer cell proliferation, cell survival and drug resistance. The levels of ROS and the activity of scavenging/antioxidant enzymes in drug resistant cancer cells are typically increased compared to non-MDR cancer and normal cells. Consequently, MDR cancer cells may be more susceptible to alterations in ROS levels (Cui et al., 2018).

More particularly, immunogenic cell death (ICD), any type of cell death eliciting an immune response, was discovered following a vaccination effect exerted by cancer cells dying from pre-treatment with certain chemotherapeutics in a murine syngeneic tumor model *in vivo*. ICD is likely to be of great relevance in cancer therapy. Interestingly, only a minority of drugs is able to trigger ICD without a clear-cut relation to chemical structures or their primary modes-of-action. Nevertheless, generation of ROS and induction of endoplasmic reticulum (ER) stress are clearly linked to ICD. Some clinically established chemotherapeutics have recently emerged as being particularly efficient in causing ICD. In the list of molecules in current clinical studies as ICD-inducing chemotherapy, doxorubicin, the first molecule in Chart 1 appears as playing a major role together with four other molecules, cyclophosphamide (**50**), oxaliplatin (**51**), epirubicin (**52**) and bortezomib (**53**) (Vanmeerbeek et al., 2020) (Chart 9).

Although cisplatin (**2**, Chart 1) and oxaliplatin (**51**) exhibit strong structural similarities, only the latter but not the former is an ICD inducer. An iron metallo-drug, P722 (**54**) has also been included in this list for the following reasons. This molecule belongs to a family of molecules called ferrocifens, that are based on the structure of hydroxy tamoxifen (OH-Tam), the antiestrogen of reference classically used to cure hormone dependent breast cancer (Jaouen et al., 2015; Top et al., 2003; Vessières, 2019). In members of the ferrocifens family, the phenyl ring of tamoxifen has been replaced by a ferrocenyl unit.

Presence of this organometallic unit confers unique redox properties to these molecules. These are associated, in cancer cells, with a high and rapid production of ROS and generation of quinone methides, highly reactive molecules able to interact with key enzymes such as thioredoxin reductase (Citta et al., 2014) and to induce cell damage leading to cell death by senescence or apoptosis (Jaouen et al., 2015; Vessières et al., 2021). As a consequence, some members of the family exhibit strong anti-proliferative effects, both *in vitro* and *in vivo*, associated with a cytotoxic activity while hydroxy tamoxifen shows only an anti-hormonal effect (Allard et al., 2008; Jaouen et al., 2015; Lainé et al., 2014). This is for example the case for P722 (**54**, Chart 9) which has been identified so far as the most cytotoxic member of the family, on MDA-MB231, triple negative breast cancer cells (IC₅₀ = 35 nM) and to be highly cytotoxic also on several MDR cell lines (Idlas et al., 2021; Wang et al., 2019). ROS production observed with ferrocifens (Jaouen et al., 2015) make them potential candidates as agent capable of inducing ICD (Terenzi et al., 2016). Indeed, in a recent paper, it has been shown that P722 formulated in lipid nanocapsules (LNCs) was able to induce an activation of CD8⁺ T lymphocytes potentially associated with an ICD inducer effect (Topin-Ruiz et al., 2021).

Immunogenic cell death agents




Chart 9. Chemical structures of molecules involved in immunogenic cell death (50-54).

Mode of Action/Targets	Compound	N°	References
P53 modulators*	doxorubicin*	1	Yang et al., 2014
	cisplatin*	2	Chen and Chang, 2004
	5-fluorouracil	3	Deng et al. 2017; Marjaneh et al., 2019
	paclitaxel*	4	Park et al., 2016
NF-kB modulators	niclosamide	5	Hamdoun et al., 2017 Li et al., 2014
	thalidomide	6	D'Amato et al., 1994
	metformin*	7	Kil-Drori et al., 2017
HIF-alpha modulators	LW6	8	Boovanahalli et al., 2007
	PX-478	9	Schwartz et al., 2010
	chetomin	10	Kung et al., 2004
	KCN1 derivative	11	Yin et al., 2012
	PT2385	12	When et al., 2018
Wnt/b-catenin modulators	LGK974	13	Liu et al., 2013
	G007-LK*	14	Huang et al., 2009
	JW55	15	Huang et al., 2009
	pyrvinium	16	Thome et al., 2010
	celecoxib	17	Tuyman et al., 2008
	genistein	18	Su and Simmen, 2009
	ICG-001	19	Emami et al., 2004
	ethyl 4-(4-trifluoromethyl)phenyl)sulfonamido) benzoate	20	Di Magno et al., 2020
FOXO modulators	selinexor KPT330)*	21	Ferreira et al., 2020
	ETP-45658	22	Link et al., 2009
	dactolisib NVP-BEZ235)	23	Serra et al., 2008
	capivasertib AZD5363)*	24	Davies et al., 2012
	tanzawaic acid D	25	Link et al., 2009
	AS1842856	26	Link et al., 2009
Pseudokinase inhibitors	TX2-121-1	27	Xie et al., 2014
	lapatinib*	28	Claus et al., 2018
	CT8	29	Ruiz-Saenz et al., 2015
	APS-2-79	30	Dhawan et al., 2016
	GW806742X	31	Hildebrand et al., 2014
	R-enantiomer cpd 4	32	Ma et al., 2016
	sunitinib	33	Ma et al., 2016
	afatinib	34	Foulkes et al., 2018
Nuclear export receptor CRM1 1 st generation)	leptomycin B	35	Hamamoto et al., Kudo et al., 1998
	1'S-1'-acetoxychavicol galangal) acetate	36	Ye and Li, 2006
	valtrate	37	Murakami et al., 2002
	callystatin	38	Murakami et al., 2002
	the simplified 39	39	Murakami et al., 2002
	piperlongumin*	40	Niu et al., 2015a
Nuclear export receptor CRM1 2 nd generation)	plumbagin	41	Liu et al., 2014
	PKF050-638	42	Daelemans et al., 2002
	CBS9106	43	Sakakibara et al., 2011
	5219668	44	Kau et al., 2003
	S109	45	Niu et al., 2015a
Nuclear export receptor CRM1 SINEs)	verdinexor KPT-335)	46	Jorquera et al., 2019
	eltanexor Z-isomer, KPT-8602)	47	Verbeke et al., 2020
	KPT-185	48	Wei et al., 2020
	KPT-276	49	Ranganathan et al., 2012
Immunogenic Cell Death (ICD)	cyclophosphamide	50	Vanmeerbeek et al. 2020
	oxaliplatin DACH-Pt)*	51	Vanmeerbeek et al. 2020
	epirubicin	52	Vanmeerbeek et al. 2020
	bortezomib	53	Vanmeerbeek et al. 2020
	ferrocifen P722*	54	Jaouen, 2015; Top, 2003; Vessieres, 2019

Table 1: List of the compounds and their molecular targets (formulated molecules with*)

N ^{**}	Compound	Formulation	Indication/ Research stage	Reference
Transcription factors				
1	doxorubicin (alone)	Pegylated liposomes Doxil [®] , Caelyx [®] , Lipdox [®])	Chemotherapy for ovarian, metastatic breast cancer, myeloma	Barenholz, 2012
2	cisplatin	Liposomal cisplatin: Lipoplatin [™]	FDA approved; orphan drug for pancreatic cancer	Boulikas, 2009, 2004; Stathopoul os and Boulikas, 2012
4	paclitaxel	Cremporphor [®] EL- Paclitaxel	Chemotherapy of or NSCLC, breast and ovarian cancer	Gelderblom et al., 2001
		Nano albumin-bound paclitaxel Abraxane [®] , nab-paclitaxel)	Chemotherapy for breast, lung and pancreatic cancers	Miele et al., 2009 ; Stinchcom be, 2007
		Paclitaxel in LNCs Labrafac [®] , PEG-HS solutol [®] (HS15)	In vitro and in vivo on glioma cancer cells	Garcion et al., 2006
7	metformin	Formulated with DOX in PLGA-TPG nanoparticles	In vitro reversion of multidrug resistance on MCF-7/DOX breast cancer	Shafiq- Irtanajad et al., 2018
14	G007-LK	Formulated in a mixture 10 % DMSO, 60 % PEG400, 30 % saline for iv and in 15 % DMSO, 17.5 Cremporphor EL, 8.75 % ethanol, 8.75 % Miglyol 810N, 50 % PBS for ip	In vitro and in vivo on CRC colorectal cancer)	Lau et al., 2013
24	AZD5363 Capivasertib	Solution containing 10 % DMSO, 25 % W/v Kleptose HPB Roquette), buffer	In vivo on xenografted breast cancer tumors BT474c, KPL-41 and HGC)	Davies et al., 2012
Pseudokinase inhibitors				
28	lapatinib	Dextran sulfate-chitosan nanoparticles	In vitro and in vivo on xenografted BT 474 cells HER ⁺ human breast cancer)	Mobasseri et al., 2017
		Polymer nanoparticles with a coordination complex of tannic acid and iron; used for lapatinib alone or for codelivery with paclitaxel	In vitro on OVCA- 432 ovarian cancer cell line); synergistic effect with paclitaxel	Levit et al., 2020
		PEG-PBC nanoparticles for codelivery of lapatinib and doxorubicin	In vitro and in vivo on xenografted breast cancer tumors MCF-7 and resistant MCF- 7/ADR)	Wang et al., 2014
Nuclear export receptors CRM1				
21	selinexor	Formulation in Pluronic F-68 non-ionic surfactant and PVP polyvinyl pyrrolidone) K- 29/32	Phase IB study for advanced refractory bone or soft tissue sarcoma	Como et al., 2018 ; Gounder et al., 2016
40	piperlongumin	Formulation in ChitoPEGse NPs obtained by crosslinking ChitoPEG [methoxy polyethylene glycol]- grafted chitosan] using selenocystine-acetyl histidine Ac-histidine)	In vitro on A549 and CT26 cells and in vivo on CT26 cell; pulmonary metastasis mouse model	Lee et al., 2018
		Encapsulation of PL in PLGA nanoparticles; co delivery with TRAIL, chemically conjugated to the surface of liposomes	In vitro on PC3 prostate and HCT116 colon cancer cells and in vivo on HCT116 cells	Sharkey et al., 2016
Associated with Immunogenic Cell Death ICD)				
1	doxorubicin	Recombinant chimeric polypeptides including doxorubicin CP-DOX)	In vitro and in vivo on 4T1-luc murine mammary carcinoma) and LL2-luc-M38 Lewis lung carcinoma)	MacKay, et al., 2009; Mastria et al., 2018

		Ultrasound controlled release of doxorubicin- liposome-microbubble complex MbDOX)	In vitro and in vivo on LL2 and CT26 cancer cells	Deng et al., 2014; Huang et al., 2018
51	oxaliplatin DACH-Pt)	Mesoporous silica nanoparticle MSNPs) loaded with oxaliplatin and subsequently encapsulated in silicasome coated lipid bilayer)	In vivo on orthotopic Kras- derived pancreatic cancer model	Liu et al., 2021
		Nano-Folox: a precipitate of the aqueous form of oxaliplatin and FNA folinic acid), formulated into an aminoethyl anisamide) PEGylated lipid nanoparticle	In vivo on orthotopic CRC colorectal cancer model)	Guo et al., 2020
		Polymer oxaliplatin prodrug nanoparticles associated with a fluorophore allowing imaging guided immunotherapy	In vivo on colorectal cancer cells	Q. Zhu et al., 2021
54	ferrocifen P722	LNCs Labrafac [®] , Lipoid [®] , PEG-HS Kolliphor [®] (HS15) surrounded by DSPE- mPEG 2000	In vivo on B16F10 mice- xenografted melanoma	Topin-Ruiz et al., 2021

Table 2: Formulation of molecules (BLPP: biotin-/lactobionic acid-modified polyethylene glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol); CRC: colorectal cancer; NPC: nasopharyngeal carcinoma; NSCLC: non-small cell lung cancer; PEG-PBC [poly(ethylene glycol)-block-poly(2-methyl-2-benzocarbonylpropylene carbonate)]; PLGA: poly(lactic-co-glycolic acid); SCCNH: squamous cell carcinoma of the head and neck; TRAIL: tumor necrosis factor-related apoptosis inducing ligand.)

Drug delivery strategies

Nanoparticulate drug delivery systems (NPs) intended to treat pathologies such as cancer or infections can provide various advantages as a high active drug loading capacity, low toxicity, targeted delivery, increased uptake by tumor cells, and optimized pharmacokinetic patterns of traditional drugs. They are expected to overcome multidrug resistance in cancer therapy. Indeed, nanotechnology holds great promise in establishing efficacious and innovative strategies to facilitate complementary treatments and cancer diagnostics, with various NPs demonstrating encouraging results (Livney and Assaraf, 2013) (Cohen, et al, 2021; Bar-Zeev, et al., 2017; Engelberg, et al., 2019). In the current review we focus on NPs adapted for the treatment of MDR tumors in the context of the emerging targets and ICD described above, which currently seem to represent innovative and promising strategies. As the bibliography is very large in this field, a focus will be put on NPs able to encapsulate the small molecules previously described in Charts 1-9 and summarized in Table 1. Table 2 presents these specific drug delivery systems as well as their *in vitro* and *in vivo* applications, when they exist.

Many reviews have broadly and recently described the different types of NPs (Fig. 2) applied to cancer therapy, including resistant cancers (Doroudian et al., 2021; Khot et al., 2021; Lepeltier et al., 2020; Mirza and Karim, 2021; Y. Zhu et al., 2021). Whether NPs are organic, inorganic or hybrid, they can be classified according to their shape (e.g., spherical, cylindrical, cubic), their size (between a few tens of nm and 1 µm), their chemical composition (polymers, lipids, gold...) and their applications. Drugs can be entrapped within, physically adsorbed, or form chemically covalent or electrostatic bonds at the surface of the nanocarrier. Some applications can be local as, for example, in the brain by convection-enhanced delivery (Allard et al., 2010) or by *in situ* injection when tumors are directly accessible (Andrade et al., 2021).

For systemic anticancer treatments, two modes of action characterize NPs according to the type of targeting they are able to achieve: passive or active targeting (Hirsjarvi et al., 2011).




Fig. 2. Different types of nanoparticles (adapted from standardnano.com)

Controversial for the past few years (Björnmalm et al., 2017; Danhier, 2016), it is nevertheless in relation with the enhanced permeability and retention (EPR) effect, characteristic of tumors that the passive targeting has been mainly evaluated (Maeda, 2021). EPR is related to the rapid and disordered growth of tumor cells by hypervascularity in a pathophysiological TME, subject to impaired lymphatic drainage. This leads to the presence of large spaces between endothelial cells and excessive secretion of vascular permeability factors allowing the NPs to specifically accumulate at the tumor site, when they are able to circulate long enough in the vascular system. To prolong this circulation, NPs are made stealth, i.e. able to escape the immune system which is prompt to eliminate them rapidly from the circulation (Bao et al., 2021). The polymer most commonly used at the surface of NPs in this context is the poly(ethylene glycol) or PEG (D'souza and Shegokar, 2016; Vonarbourg et al., 2006), but other surface coating with poly(2-oxazoline), poly(zwitterions) (Fam et al., 2020) or polysaccharides as chitosan (Moraru et al., 2020) have been employed. These molecules are generally low in charge, biocompatible and very flexible. The influence of the composition, size and conformation of these surface molecules has been widely described in the literature (Ozer et al., 2017; Vonarbourg et al., 2006). With such a protective layer and thanks to a steric effect, NPs are able to repel the absorption of opsonin proteins and block the uptake by macrophages.

However, by passive targeting, a high untoward toxicity can be observed through the action of NPs on the healthy cells of the TME, resulting in significant side effects (Attia et al., 2019; Bazak et al., 2015; Izci et al., 2021; Pérez-Herrero and Fernández-Medarde, 2015). To achieve greater specificity, active targeting can be attained by conjugation of targeting ligands (e.g. antibodies, peptides, small molecule ligands) to the NPs (Ashfaq et al., 2017) or through the use of an external or internal stimulus to the desired location (Liu et al., 2020). Different targeting moieties, such as albumin, folic acid, somatostatin, and transferrin, can be attached to NP surface with a particular affinity for transmembrane receptors present at the surface of tumor cells, allowing an enhancement of the site-specificity and receptor-mediated endocytosis (Yu et al., 2012) (Pinhassi, et al., 2010; Assaraf, et al., 2014). Efficient binding and internalization require that receptors are expressed exclusively on target cancer cells relative to normal cells, and expression should be homogenous across all targeted cells (Peer et al., 2007). Targeted NPs offer innovative therapeutic strategies to overcome the various limitations of conventional chemotherapy, enabling enhanced selectivity, early and more precise cancer diagnosis, individualized treatment as well as overcoming of MDR (Bar-Zeev et al., 2017).

Although more advanced technologies are needed to assess the interactions between NPs and biological systems, new treatments are emerging by combining different strategies involving NPs. Indeed, multicomponent or multifunctional systems (one or more drugs, bioactive moieties reacting with external or internal stimuli, and imaging functions) combined with different types of therapeutics (radiation, photodynamic therapy, gene therapy, immunotherapy, etc.) can increase the effective concentration of chemotherapeutic drugs in tumor cells as well as minimize the risk of resistance, improving therapeutic efficacy by modulating the different pathways involved (Chen et al., 2020; Gao et al., 2020; Liu et al., 2018). Drug combination therapy has long been adopted as the standard first-line treatment of several malignancies to improve the clinical outcome and combination with NPs has been shown to generally induce synergistic activity and sometimes prevent the onset of drug resistance (Gurunathan

et al., 2020). Indeed, NPs-based combination therapy can deliver multiple therapeutic agents with different physicochemical and pharmacological properties. For example, one drug will reverse or abolish the development of drug resistance, whereas the other will concurrently kill cancer cells. Different examples using ferrocifen LNCs proved that the action of the active drug was improved when external radiotherapy was applied (Allard et al., 2010) or when BCL-2 gene therapy was associated via the siRNA co-encapsulation with the iron-based drug (Resnier et al., 2017).

Accumulating evidence shows that the expression of biomarkers related to stemness is crucial for tumor maintenance as they are also the mediators of drug resistance. This evidence is of special relevance since cancer stem-like cells (CSC) have been shown to be drivers of metastasis, associated with a more invasive and aggressive cancer phenotype (Garcia-Mayea et al., 2020). Thus, the phenomenon of cancer MDR can be related both to rapidly proliferating cells constituting the bulk of the tumor but also to CSC localized in tumor niches, difficult to target, able to survive to conventional therapy and leading to recurrent disease. These cells have a natural tendency to migrate and distribute within the tumor mass with a specific tropism. As an example, "marrow-isolated adult multilineage inducible" cells (MIAMI cells), a subpopulation of mesenchymal stromal cells, were able to efficiently incorporate LNCs without altering their stem cell properties or their migration capacity. MIAMI cells loaded with LNCs containing a ferrocifen produced a significant cytotoxic effect on U87MG glioma cells *in vitro* and *in vivo* after intratumor injection in a heterotopic U87MG glioma model in nude mice (Clavreul et al., 2015; Roger et al., 2012).

Based on all this data, the development of "quadrugnostic" NPs as proposed by Shapira et al., (Shapira et al., 2011) harboring i) a selective targeting moiety, ii) a diagnostic imaging component, iii) an anticancer drug and iv) an anti MDR agent, will allow novel personalized medicine treatment modalities able to surmount distinct and well-defined mechanisms of anticancer drug resistance (Assaraf et al., 2019). To achieve the most out of NPs therapy in cancer treatment, new delivery systems have also to be selected based on the characteristics of the tumor. Personalized treatments according to the characteristics of the TME showing high intra- and inter-tumor variability, can be adapted to enhance tumor penetration by developing different design parameters in accordance with the tumor physiology (Swetha and Roy, 2018). Many reviews detail the characteristics of the TME and the various strategies that can be deployed to take advantage of it (Baghban et al., 2020). For example, modification of NP surface by pH-sensible polymers can represent a way to increase the cellular uptake in the acidic TME, enhancing tumor sensitivity to anticancer drugs (Donahue et al., 2019; Pautu et al., 2021). Finally, as emerging components of the tumor-host interaction, tumor-derived circulating materials as exosomes are increasingly recognized as professional carriers of information in TME and as pivotal molecular entities involved in tumorigenic microenvironment setup (Wu et al., 2019). Furthermore, they can also be used as cancer diagnostic tools to precisely predict and monitor the outcome of therapy. Recently, widely described in the literature and somewhat marginal to our purpose, this topic will not be developed in this review (Le Saux et al., 2020; Lepeltier et al., 2020; Li et al., 2020; Mashouri et al., 2019; Wortzel et al., 2019).

Metastatic lesions show genetic instability that gives rise to mutations also conferring drug resistance. They usually show heterogeneous subpopulations of cells, different from the original primary tumor cells, with differential gene expression patterns, growth properties, cell surface proteins, and enzyme/protein functions. Furthermore, the molecular and cellular signatures can vary both within single metastases and among different metastases. As a consequence, among drugs showing high cytotoxic effect *in vitro* and *in vivo* in preclinical mouse models, only a few reached clinical trials due to the lack of sensitivity of metastatic cells (Banerjee et al., 2019). Multiple ongoing clinical trials are directed towards nanomedicine-based strategies including combination

therapies with the specific objective of eliminating the tumor and its metastasis (combination of chemotherapeutic agents, ICIs, inhibitors of angiogenesis, a process that is often associated with metastasis). Currently, more than a dozen of clinically approved NPs is successfully used for various types of cancer treatments. Majority of NPs are derived from liposomes and polymers (Table 2). Complexity of chemical synthesis or multistage processes, posing a significant challenge in obtaining consistent physical and chemical properties (size, composition over time) at affordable price, can compromise the successful clinical translation. A better understanding of the tumor type-specific pathophysiology, more connections between research and treatment and NP design based on patient characteristics (biomarker preselection strategies, treatment combinations with a clinical focus on the target disease as it develops in patients) must be implemented to achieve this success (Nayak et al., 2021).

Nanoparticulate drug delivery systems (NPs) used to deliver some of the selected drugs

As previously described, the mechanisms by which cancer cells develop MDR are well known and among them are: (i) enhanced tumor cell proliferation and pro-survival signals, (ii) increased drug efflux, (iii) decreased drug uptake, (iv) drug inactivation, (v) evasion of drug-induced apoptosis, (vi) activation of DNA repair, (vii) acquired DNA mutation, (viii) epithelial to mesenchymal phenotype transition, (ix) epigenetic modifications. One main advantage of NPs is their ability to harbor a very wide spectrum of small anti-cancer molecules. This is especially true for hydrophobic drugs, molecules with a low therapeutic index or even unstable drugs (Da Silva et al., 2017). Among the 54 molecules detailed in Table 1, we will focus on 11 of them requiring formulation in NPs for *in vitro* and *in vivo* studies on MDR tumor cells. Formulation used for these molecules ranges from simple to very sophisticated ones (Table 2). Most of the time, NPs are fully characterized by their size, zeta potential, drug loading, encapsulation efficiency and release kinetics. Numerous formulations of three blockbuster listed in Table 1 (doxorubicin, paclitaxel, and cisplatin) have been published in the literature including co-formulations with other molecules. This is for example the case for doxorubicin (1) and paclitaxel (4) which have been encapsulated with targeting moieties improving prostate cancer treatment (Cohen et al., 2021). Here, we will focus on representative formulation of these drugs alone, or co-encapsulated with other drugs from our panel and associated with the 4 targets previously identified (non-liganded transcription factors, pseudokinases, nuclear export receptors and immune cell death regulators).

NPs and molecules associated with transcription factors

This first series contains the highest number of molecules (6 molecules). The first one in the list is doxorubicin (DOX), the first antitumor agent whose formulation in PEGylated liposomes was approved in 1995 for cancer treatment (Barenholz, 2012). The need for formulation of DOX was imposed because of its high cardiotoxicity. In this first formulation marketed under the names CAELYX®, DOXIL®, LIPODOX®, DOX is solubilized in a liposome which is then protected by a PEG layer. This formulation is used for chemotherapeutic treatment of multiple cancers for example ovarian cancer, endometrial cancer, metastatic breast cancer, multiple myeloma and lymphoma. Two formulations enhancing the ICD effect of DOX have been published and will be described below. The second molecule in the list is cisplatin (2), a potent metalloid drug used to treat many forms of cancers (metastatic testicular, ovarian, NSCLC, cervical cancers, and head and neck cancer). It is usually given by infusion of its saline solution. However, due to its numerous side effects, the search for nanoformulations aimed at reducing its toxicity has been explored. The main successful one so far is a liposomal cisplatin formulation, called Lipoplatin™ which is FDA-approved (Boulikas, 2009, 2004; Stathopoulos and Boulikas, 2012; Xu et al., 2018). This formulation was achieved by

formation of reverse micelles between cisplatin and DPPG (dipalmitoyl phosphatidyl glycerol) under special conditions of pH, ethanol and ionic strength. The cisplatin-DPPG reverse micelles were subsequently converted into liposomes by interaction with neutral lipids (mPEG 2000-DSPE). The nanoparticles, 110 nm in diameter, have the ability to target tumors and metastasis following intravenous administration. (Boulikas, 2009, 2004; Stathopoulos and Boulikas, 2012). Lipoplatin has been granted “orphan drug formulation” for pancreatic cancer treatment by the European Medicine Agency. Lipoplatin has 14-fold better radiosensitizing activity than cisplatin. Many preclinical and clinical trials on lipoplatin have been carried out over the past 2 decades. A recent meta-analysis of five clinical trials on NSCLC (non-small cell lung cancer) and SCCHN (squamous cell carcinoma of the head and neck) cells revealed that this formulation offers significant advantages regarding progression of the disease and reduced toxicities relative to cisplatin (Xu et al., 2018).

The third molecule in the list is paclitaxel (4), a highly lipophilic molecule. Actually, after the identification of this molecule as the active ingredient in crude ethanolic extracts of the bark of the pacific Yew tree against several tumors, its development was suspended for more than a decade due to problems associated with its solubility. Paclitaxel is insoluble in water (less than 0.03 mg/ml) but soluble in Cremophor® EL (CrEL) a non-ionic surfactant (Gelderblom et al., 2001). CrEL is produced by the reaction of castor oil with ethylene oxide and consists mainly of oxylated triglycerides of ricinoleic acid. In its pharmaceutical form, paclitaxel is dissolved in a mixture of CrEL and dehydrated ethanol (1:1 v/v). Paclitaxel is prescribed for many cancers including MDR ones (ovarian, metastatic breast cancer, multiple myeloma). An albumin-bound formulation of paclitaxel (nab-paclitaxel, Abraxane®) was published in 2007 (Miele et al., 2009; Stinchcombe, 2007). This CrEL free formulation is prepared by high-pressure homogenization of paclitaxel in the presence of serum albumin into a nanoparticle (average size 130 nm) colloidal suspension. This formulation eliminates the impact of CrEL on paclitaxel pharmacokinetics and utilizes the endogenous albumin transport mechanisms to concentrate Abraxane® within the tumor. Abraxane® is used as a chemotherapeutic agent for breast, lung and pancreatic cancer. Abraxane® anticancer activity has been studied in association with other chemotherapeutic agents or radiotherapy in various clinical I and II trials (Banerjee et al., 2019). Paclitaxel has also been formulated in lipid nanocapsules (LNCs) consisting of an oily core of triglycerides (Labrafac®) able to solubilize paclitaxel, surrounded by lecithin (Lipoid®) and a surfactant (PEG-HS Solutol® HS15) (Garcion et al., 2006). These paclitaxel-LNCs have been tested *in vitro* and *in vivo* on glioma cells and were found more efficient than the commercially available paclitaxel formulation. The fourth molecule, Metformin (7) has been recently co-encapsulated with DOX in PLGA-TPG nanoparticles [poly(lactide-co-glycolide)-d-alpha-tocopheryl polyethylene glycol nanoparticles] (Shafiei-Irannejad et al., 2018). This NPs were tested, *in vitro*, on MCF-7/DOX cancer cells resistant to DOX and a synergistic effect of the two drugs was observed. The fifth molecule G007-LK (14), has been formulated in a mixture of 10% DMSO, 60% PEG400, 30% saline for i.v. administration as well as in 15% DMSO, 17.5% CrEL, 8.75% ethanol, 8.75% Miglyol 810N, 50% PBS for intraperitoneal injection (Lau et al., 2013). G007-LK NPs were found to inhibit tumor growth of APC-mutant colorectal cancer cells both *in vitro* and *in vivo*. AZD5363 (Capivasertib; 24), the sixth molecule is an orally active and potent pan-AKT kinase inhibitor. It has been formulated in a solution containing 10% DMSO, 25% w/v Kleptose HPB (Roquette) buffer and is administered by oral gavage (Davies et al., 2012). In line with its mode of action, the growth inhibitory effect of AZD5363 is more pronounced in cells with PIK3CA and PTEN mutations but less pronounced in cells with RAS mutations. In addition, it enhances the activity of HER2 inhibitors and docetaxel *in vivo*.

NPs and molecules associated with pseudokinase inhibitors

Lapatinib (**28**) is the only molecule in this series. It is a TKI marketed under the trade name of TYKERB® and administered as lapatinib ditosylate monohydrate in an oral form (Lapatinib, 2015). However, its clinical use is restricted because of its extensive albumin binding capacity and poor oral bioavailability (Bonde et al., 2018). Consequently, numerous formulations of lapatinib have been developed. For example, lapatinib has been formulated in dextran sulfate-chitosan NPs (Mobasser et al., 2017) or in polymer NPs (Levit et al., 2020). In this case, flash nano precipitation (FNP) is used to self-assemble PEG nanoparticles (PS-b-PEG; polystyrene-b-polyethylene glycol) with lapatinib and a coordination complex of tannic acid and iron. This formulation has also been used for codelivery of paclitaxel and lapatinib (Levit et al., 2020) and a synergistic effect of the two drugs was observed. Another formulation was also developed for the codelivery of doxorubicin and lapatinib (Wang et al., 2014). This time, the two drugs were encapsulated in polymer micelles of PEG-PBC [poly(ethylene glycol)-block-poly(2-methyl-2-benzocarbonylpropylene carbonate)] and lapatinib was used as an adjuvant sensitized drug in breast cancer cells resistant to doxorubicin (MCF-7/ADR) (Wang et al., 2014).

NPs and molecules associated with nuclear export receptors CRM1

Two molecules belong to this category. The first one is selinexor (KPT-330, **21**) which is formulated in a non-ionic surfactant (Pluronic F-68) and a polymer (Plasdone K-29/32 PVP). A synergistic interaction between cisplatin and selinexor has been observed in ovarian carcinoma cells (Corno et al., 2018). The second one is piperlongumine (PL, **40**). Two formulations exist for this molecule. In the first one, PL is encapsulated in nanoparticles of chitosan as follows: chitoPEG [methoxy poly(ethylene glycol)-grafted chitosan] are crosslinked using selenocystine-acetyl histidine (Ac-histidine) conjugates thus giving ChitoPEGse (Lee et al., 2018). ChitoPEGse NPs are delivered to cancer cells in an acidic- or redox state-sensitive manner, allowing their efficient targeting of pulmonary metastasis of cancer cells (CT26) in a mouse model. In the second one, PL is encapsulated in PLGA nanoparticles and used to deliver a combination of two drugs, namely PL and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) chemically conjugated to the surface of liposomes (Sharkey et al., 2016). Higher apoptotic rates were observed for HTC116 tumor cells that received the dual nanoparticle therapy compared to individual stages of the therapy alone.

NPs and molecules associated with immunogenic cell death (ICD)

Three molecules are in this category; the first one is DOX, already cited in the part concerning transcription factors. Actually, two specific formulations have been described in connection with ICD. The first one, is a sophisticated formulation, where DOX is encapsulated in NPs consisting of two segments, a hydrophilic, biodegradable elastin-like polypeptide and a short segment for the attachment of DOX through a pH labile linker. Chimeric polypeptides (CPs) self-assemble into CP-DOX (sub-100 nm in size) (MacKay, et al., 2009). When used to deliver DOX to murine cancer model, these NPs have a fourfold higher maximal dose than the free drug and induce nearly complete tumor regression after a single dose. These NPs were also found to enhance antitumor immunity compared to free DOX and to re-establish host antitumor immunity through the generation of ICD (Mastria et al., 2018). In the second formulation, DOX-liposome-microbubble complexes (DLMC) were prepared through conjugation of DOX liposomes (DL) to the surface of microbubbles (made of perfluoropropane C3F8) via the high affinity biotin-streptavidin binding (Deng et al., 2014). These NPs, activated by ultrasound, were able to induce ICD more efficiently than free doxorubicin (Huang et al., 2018). Oxaliplatin is the second drug in the list; oxaliplatin (DACH-Pt) is one of the three platinum drugs classically prescribed in

cancer chemotherapy. Oxaliplatin is often administered without formulation but recently three formulations have been published and are associated with the effect of the drug as an ICD inducer. The first one consists of the preparation of mesoporous silica nanoparticles (MSNPs) loaded with oxaliplatin through the use of electrostatic and coordination chemistry under weak basic pH conditions. These MSNPs are then encapsulated in a coated lipid bilayer (silicasome) to improve its stability after i.v. injection (Liu et al., 2021). These NPs induce ICD but interestingly, are also associated with a dramatic reduction in bone marrow toxicity (Liu et al., 2021). The second one is Nano-Folox, a formulation derived from FOLFOX, the combination of oxaliplatin with 5-fluorouracil (5-FU) and folinic acid (FnA) used as standard treatment of CRC. In Nano-Folox, the active hydrolysed form of oxaliplatin, [Pt(DACH)(H₂O)₂]²⁺, is precipitated with FnA then formulated into an (aminoethyl anisamide) PEGylated lipid nanoparticle (Guo et al., 2020). Nano-Folox significantly promoted blood circulation of the NPs and induced a stronger chemotherapeutic response than that of FOLFOX in an orthotopic CRC mouse model (Guo et al., 2020). The third formulation is an oxaliplatin prodrug NPs with near-infrared fluorescence properties (Q. Zhu et al., 2021). This formulation elicits antitumor immune response and allows near infrared fluorescence imaging-guided for photothermal therapy (Guo et al., 2020). The last component in this series is P722 (**54**), a member of the ferrocifen family. These molecules are lipophilic thus they can be *in vivo* administered only after formulation. It has been shown by Passirani and her group that lipid nanocapsules are a very well-suited formulation for this family of molecules (Idlas et al., 2021). These nanoparticles present a hybrid structure between polymer NPs and liposomes and are prepared by a solvent-free process. They are composed of an oily core allowing dissolution of the lipophilic entity, surrounded by a shell of lecithin and PEG surfactant (Heurtault et al., 2002). These LNCs loaded with P722 have been tested on B16F10 melanoma mouse model (Topin-Ruiz et al., 2021). *In vivo*, a significant improvement in the survival rate and tumor progression was observed with P722-loaded LNCs in comparison with anti-CTLA4 mAb, the treatment of reference, identifying an immune-preventive approach of P722.

Conclusion and future perspectives

Proteins lacking catalytic activities, or ligand-binding pockets or for which no experimental three-dimensional structure are available, have been considered undruggable. Progress in drug discovery and development technologies including artificial intelligence, computer-based drug design, RNA therapeutics, targeted protein degradation, peptide-based and protein-based drugs are currently and will continue to broadening the landscape of druggability. As a consequence, a variety of historically undruggable, clinically meaningful therapeutic proteins will become important novel pharmacological targets. Indeed, the very concept of "undruggable" will vanish in the near future. The current review article provided some paradigmatic examples for this process.

A broad range of diverse chemical inhibitors and small molecule modulators of the activity of transcription factors and pseudokinase function have been identified to interfere with these targets. Several of these drug candidates are in different phases of development. The identification of compounds interfering with the activity of FOXO proteins has made significant progress (Calissi, et al. 2021). FOXO proteins are becoming an attractive target for reseracher from both academia and pharma industry. The importance of pseudokinases, that are unusual types of kinases, is growing since their role in normal physiological processes and in the onset of diseases are increasingly understood. Much of what we have learned from drugging active kinases can be applied to targeting pseudokinases and vice versa (Kung and Jura, 2019). Efforts have been made towards the development of inhibitors of the nuclear export receptor protein CRM1 as it was recognized that cells become vulnerable to cancer after the nuclear export of many tumor suppressors and oncoproteins by CRM1 (Nguyen, et al., 2012). As non-liganded transcription factors and pseudokinases, CRM-1

lacks catalytic activity and operates via biomolecule interactions.

Here we proposed a knowledge-based strategy towards the discovery of targeted anti-cancer drugs in order to overcome drug resistance and render drug resistant cancer cells responsive to therapy. Recent progress in drug development technologies facilitated the targeting of difficult protein targets such as pseudokinases, unliganded transcription factors and nuclear export receptors thereby realizing the therapeutic potential of these approaches.

The continued development of nanomedicines has the potential to provide numerous benefits, including improved efficacy, bioavailability and targeting ability of undruggable molecules, compared to conventional medicines. In the examples described in this review, we have shown that NPs present new opportunities to improve safety and efficacy of conventional therapeutics. It also opens the possibility of delivering drugs with low bioavailability.

Application of these new strategies in the treatment of patients is related to the development of personalized medicine or individualized medicine. This approach aims to analyze the characteristics of individual tumors and thus identify those that are likely to respond to a targeted therapy. Interest of this approach has been highlighted, for example, in the treatment of prostate cancer (Cohen, et al., 2021), glioblastoma (Vessières, et al., 2021b) and colorectal cancer (Kim, et al., 2012). It is becoming more and more important in the treatment of patients.

Declaration of Competing Interest

The authors declare no conflict of interest. The authors R.S., C.P., A. V. and G. La R. declare no conflict of interest. Wolfgang Link is the scientific co-founder of Refoxy Pharmaceuticals GmbH, Berlin and is required by his institution to state so in his publications. The funders had no role in the design and writing of the manuscript.

Acknowledgements

This article is based upon work from COST Action STRATAGEM, CA17104, supported by COST (European Cooperation in Science and Technology) (www.cost.eu, accessed in July 2021). The authors would like to thank this COST Action "New diagnostic and therapeutic tools against multidrug resistant tumors" and the Agence Nationale de la Recherche (ANR PRCE NaTeMOc N_ ANR-19-CE18-0022-01) for its financial support. R.S. is indebted to AIRC, IG 2020, code n. 24703. G.L.R. thanks Istituto Pasteur Italia - Fondazione Cenci Bolognetti (Call 2019, under 45) and Sapienza Università di Roma (RP11715C7D1CF0D1 and RM11916B5598E3C4) for financial support. This work was supported by the FUNDAÇÃO PARA A CIÊNCIA E TECNOLOGIA (FCT) Research Center Grant UID/BIM/04773/2013, Centre for Biomedical Research (CBMR), and by the Spanish Ministry of Science, Innovation and Universities through Grant RTI2018-094629-B-I00 to WL.

References

Adams, D.J., Dai, M., Pellegrino, G., Wagner, B.K., Stern, A.M., Shamji, A.F., Schreiber, S.L., 2012. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. *Proc Natl Acad Sci U S A* 109, 15115–15120. <https://doi.org/10.1073/pnas.1212802109>

Aghi, M., Hochberg, F., Breakefield, X.O., 2000. Prodrug activation enzymes in cancer gene therapy. *J Gene Med* 2, 148–164. [https://doi.org/10.1002/\(SICI\)1521-2254\(200005/06\)2:3<148::AID-JGM105>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q)

Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., and 347 others, 2015. Genomic Classification of Cutaneous Melanoma. *Cell* 161, 1681–1696. <https://doi.org/10.1016/j.cell.2015.05.044>

Allard, E., Jarnet, D., Vessières, A., Vinchon-Petit, S., Jaouen, G., and 2 others, 2010. Local Delivery of Ferrociphenol Lipid Nanocapsules Followed by External Radiotherapy as a Synergistic Treatment Against Intracranial

9L Glioma Xenograft. *Pharm Res* 27, 56–64. <https://doi.org/10.1007/s11095-009-0006-0>

Allard, E., Passirani, C., Garcion, E., Pigeon, P., Vessières, A., and 2 others, 2008. Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. *Journal of Controlled Release* 130, 146–153. <https://doi.org/10.1016/j.jconrel.2008.05.027>

Amakye, D., Jagani, Z., Dorsch, Z., 2013. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. *Nat Med* 19, 1410–1422. <https://doi.org/10.1038/nm.3389>

Andrade, F., Roca-Melendres, M.M., Durán-Lara, E.F., Rafael, D., Schwartz, S., 2021. Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field. *Cancers* 13, 1164. <https://doi.org/10.3390/cancers13051164>

Antoszczak, M., Markowska, A., Markowska, J., Huczyński, A., 2020. Old wine in new bottles: Drug repurposing in oncology. *Eur J Pharmacol* 866, 172784. <https://doi.org/10.1016/j.ejphar.2019.172784>

Arany, Z., Huang, L.E., Eckner, R., Bhattacharya, S., Jiang, C., and 3 others, 1996. An essential role for p300/CBP in the cellular response to hypoxia. *Proc Natl Acad Sci U S A* 93, 12969–12973. <https://doi.org/10.1073/pnas.93.23.12969>

Armando, R.G., Mengual Gómez, D.L., Gomez, D.E., 2020. New drugs are not enough-drug repositioning in oncology: An update. *Int J Oncol* 56, 651–684. <https://doi.org/10.3892/ijo.2020.4966>

Ashfaq, U.A., Riaz, M., Yasmeen, E., Yousaf, M.Z., 2017. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment. *Crit Rev Ther Drug Carrier Syst* 34, 317–353. <https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2017017845>

Assaraf, Y.G., Molina, A., SchMike, R.T., 1989. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. *J Biol Chem* 264, 18326–18334. <https://pubmed.ncbi.nlm.nih.gov/2572592/>

Assaraf, Y.G., Feder, J.N., Sharma, R.C., and 4 others., 1992. Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts. *J Biol Chem* 267, 5776–5784. <https://pubmed.ncbi.nlm.nih.gov/1372892/>

Assaraf Y, 2007. Molecular basis of antifolate resistance. *Cancer Metastasis Rev* 26, 153–181. <https://link.springer.com/article/10.1007%2Fs10555-007-9049-z>

Assaraf, Y.G., Leamon, C., Reddy, J.A., 2014. The folate receptor as a rational therapeutic target for personalized cancer treatment. *Drug Resist Updat* 17, 89–95. <https://doi.org/10.1016/j.drug.2014.10.002>

Assaraf, Y.G., Brozovic, A., Gonçalves, A.C., Jurkovicova, D., Linē, A., and 5 others, 2019. The multi-factorial nature of clinical multidrug resistance in cancer. *Drug Resistance Updates* 46, 100645. <https://doi.org/10.1016/j.drug.2019.100645>

Attia, M.F., Anton, N., Wallyn, J., Omran, Z., Vandamme, T.F., 2019. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. *Journal of Pharmacy and Pharmacology* 71, 1185–1198. <https://doi.org/10.1111/jphp.13098>

Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., and 4 others, 2020. Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Commun Signal* 18, 59. <https://doi.org/10.1186/s12964-020-0530-4>

Bailey, F.P., Byrne, D.P., Oruganty, K., Evers, C.E., Novotny, C.J., and 3 others, 2015. The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner. *Biochem J* 467, 47–62. <https://doi.org/10.1042/BJ20141441>

- Banerjee, D., Cieslar-Pobuda, A., Zhu, G.H., Wiechec, E., Patra, H.K., 2019. Adding Nanotechnology to the Metastasis Treatment Arsenal. *Trends in Pharmacological Sciences* 40, 403–418. <https://doi.org/10.1016/j.tips.2019.04.002>
- Bao, J., Zhang, Q., Duan, T., Hu, R., Tang, J., 2021. The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery. *CDT* 22, 922–946. <https://doi.org/10.2174/1389450122666210118105122>
- Barenholz, Y. (Chezy), 2012. Doxil® — The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release* 160, 117–134. <https://doi.org/10.1016/j.jconrel.2012.03.020>
- Bar-Zeev, M., Livney, Y.D., Assaraf, Y.G., 2017. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. *Drug Resistance Updates* 31, 15–30. <https://doi.org/10.1016/j.drug.2017.05.002>
- Bazak, R., Houry, M., El Achy, S., Kamel, S., Refaat, T., 2015. Cancer active targeting by nanoparticles: a comprehensive review of literature. *J Cancer Res Clin Oncol* 141, 769–784. <https://doi.org/10.1007/s00432-014-1767-3>
- Benson, J.D., Chen, Y.-N.P., Cornell-Kennon, S.A., Dorsch, M., Kim, S., Leszczyniecka, M., and 2 others, 2006. Validating cancer drug targets. *Nature* 441, 451–456. <https://doi.org/10.1038/nature04873>
- Björnmalm, M., Thurecht, K.J., Michael, M., Scott, A.M., Caruso, F., 2017. Bridging Bio-Nano Science and Cancer Nanomedicine. *ACS Nano* 11, 9594–9613. <https://doi.org/10.1021/acs.nano.7b04855>
- Bonavida, B., Baritaki, S., 2011. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF- κ B/Snail/YY1/RKIP circuitry. *Nitric Oxide* 24, 1–7. <https://doi.org/10.1016/j.niox.2010.10.001>
- Bonavida, B., Baritaki, S., Huerta-Yepez, S., Vega, M.I., Chatterjee, D., and 1 other, 2008. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. *Nitric Oxide* 19, 152–157. <https://doi.org/10.1016/j.niox.2008.04.018>
- Bonde, G.V., Yadav, S.K., Chauhan, S., Mittal, P., Ajmal, G., and 2 others, 2018. Lapatinib nano-delivery systems: a promising future for breast cancer treatment. *Expert Opinion on Drug Delivery* 15, 495–507. <https://doi.org/10.1080/17425247.2018.1449832>
- Bondeson, D.P., Mares, A., Smith, I.E.D., Ko, E., Campos, S., and 24 others, 2015. Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol* 11, 611–617. <https://doi.org/10.1038/nchembio.1858>
- Boovanahalli, S.K., Jin, X., Jin, Y., Kim, J.H., Dat, N.T., and 5 others, 2007. Synthesis of (aryloxyacetyl)amino-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1 α inhibitors. *Bioorg Med Chem Lett* 17, 6305–6310. <https://doi.org/10.1016/j.bmcl.2007.09.005>
- Borst, P., Evers, R., Kool, M., Wijnholds, J., 1999. The multidrug resistance protein family. *Biochim Biophys Acta* 1461, 347–357. [https://doi.org/10.1016/s0005-2736\(99\)00167-4](https://doi.org/10.1016/s0005-2736(99)00167-4)
- Boudeau, J., Miranda-Saavedra, D., Barton, G.J., Alessi, D.R., 2006. Emerging roles of pseudokinases. *Trends Cell Biol* 16, 443–452. <https://doi.org/10.1016/j.tcb.2006.07.003>
- Boulikas, T., 2009. Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin. *Expert Opinion on Investigational Drugs* 18, 1197–1218. <https://doi.org/10.1517/13543780903114168>
- Boulikas, T., 2004. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. *Oncol Rep* 12, 3–12.
- Bouyssou, J.M.C., Ghobrial, I.M., Roccaro, A.M., 2016. Targeting SDF-1 in multiple myeloma tumor microenvironment. *Cancer Lett* 380, 315–318. <https://doi.org/10.1016/j.canlet.2015.11.028>
- Brennan, D.F., Dar, A.C., Hertz, N.T., Chao, W.C.H., Burlingame, A.L., and 2 others, 2011. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. *Nature* 472, 366–369. <https://doi.org/10.1038/nature09860>
- Brenner, D., Blaser, H., Mak, T.W., 2015. Regulation of tumour necrosis factor signalling: live or let die. *Nat Rev Immunol* 15, 362–374. <https://doi.org/10.1038/nri3834>
- Brown, A.K., Webb, A.E., 2018. Regulation of FOXO Factors in Mammalian Cells. *Curr Top Dev Biol* 127, 165–192. <https://doi.org/10.1016/bs.ctdb.2017.10.006>
- Burgering, B.M.T., 2008. A brief introduction to FOXology. *Oncogene* 27, 2258–2262. <https://doi.org/10.1038/onc.2008.29>
- Burslem, G.M., Crews, C.M., 2020. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. *Cell* 181, 102–114. <https://doi.org/10.1016/j.cell.2019.11.031>
- Bushweller, J.H., 2019. Targeting transcription factors in cancer — from undruggable to reality. *Nat Rev Cancer* 19, 611–624. <https://doi.org/10.1038/s41568-019-0196-7>
- Cabal-Hierro, L., Lazo, P.S., 2012. Signal transduction by tumor necrosis factor receptors. *Cell Signal* 24, 1297–1305. <https://doi.org/10.1016/j.cellsig.2012.02.006>
- Calissi, G., Lam, E.W.-F., Link, W., 2021. Therapeutic strategies targeting FOXO transcription factors. *Nat Rev Drug Discov* 20, 21–38. <https://doi.org/10.1038/s41573-020-0088-2>
- Calnan, D.R., Brunet, A., 2008. The FoxO code. *Oncogene* 27, 2276–2288. <https://doi.org/10.1038/onc.2008.21>
- Cao, X., Hou, J.H., Assaraf, Y.G., Wang, X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. *Drug Resist Updat* 19, 100671. <https://doi.org/10.1016/j.drug.2019.100671>
- Capdeville, R., Buchdunger, E., Zimmermann, J., Matter, A., 2002. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. *Nat Rev Drug Discov* 1, 493–502. <https://doi.org/10.1038/nrd839>
- Cautain, B., de Pedro, N., Murillo Garzón, V., Muñoz de Escalona, M., González Menéndez, V., and 8 others. High-Content Screening of Natural Products Reveals Novel Nuclear Export Inhibitors. *J Biomol Screen* 19, 57–65. <https://doi.org/10.1177/1087057113501389>
- Chan, K.-T., Lung, M.L., 2004. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. *Cancer Chemother Pharmacol* 53, 519–526. <https://doi.org/10.1007/s00280-004-0767-4>
- Chen, M.-L., Lai, C.-J., Lin, Y.-N., Huang, C.-M., Lin, Y.-H., 2020. Multifunctional nanoparticles for targeting the tumor microenvironment to improve synergistic drug combinations and cancer treatment effects. *J. Mater. Chem. B* 8, 10416–10427. <https://doi.org/10.1039/D0TB01733G>
- Chen, S.-H., Chang, J.-Y., 2019. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. *Int J Mol Sci* 20. <https://doi.org/10.3390/ijms20174136>
- Choi, C.-H., 2005. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. *Cancer Cell Int* 5, 30. <https://doi.org/10.1186/1475-2867-5-30>
- Citta, A., Folda, A., Bindoli, A., Pigeon, P., Top, S., and 4 others, 2014. Evidence for Targeting Thioredoxin Reductases with Ferrocenyl Quinone Methides. A Possible Molecular Basis for the Antiproliferative Effect of Hydroxyferrocifens on Cancer Cells. *J. Med. Chem.* 57, 8849–8859. <https://doi.org/10.1021/jm5013165>
- Clarke, A.R., Gledhill, S., Hooper, M.L., Bird, C.C., Wyllie, A.H., 1994. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. *Oncogene* 9, 1767–1773.
- Claus, J., Patel, G., Autore, F., Colomba, A., Weitsman, G., and 15 others, 2018. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. *Elife* 7. <https://doi.org/10.7554/eLife.32271>
- Clavreul, A., Lautram, N., Franconi, F., Passirani, C., Montero-Menei, C., and 5 others, 2015. Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules. *IJN* 1259. <https://doi.org/10.2147/IJN.S69175>
- Clevers, H., Loh, K.M., Nusse, R., 2014. Stem cell signaling. An integral program for tissue renewal and

- regeneration: Wnt signaling and stem cell control. *Science* 346, 1248012. <https://doi.org/10.1126/science.1248012>
- Clevers, H., Nusse, R., 2012. Wnt/ β -catenin signaling and disease. *Cell* 149, 1192–1205. <https://doi.org/10.1016/j.cell.2012.05.012>
- Cohen, L., Livney, Y.D., Assaraf, Y.G., 2021. Targeted nanomedicine modalities for prostate cancer treatment. *Drug Resistance Updates* 56, 100762. <https://doi.org/10.1016/j.drug.2021.100762>
- Corno, C., Stucchi, S., De Cesare, M., Carenini, N., Stamatakis, S., and 8 others, 2018. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. *Biochem Pharmacol* 147, 93–103. <https://doi.org/10.1016/j.bcp.2017.11.009>
- Cromm, P.M., Crews, C.M., 2017. Targeted Protein Degradation: from Chemical Biology to Drug Discovery. *Cell Chemical Biology* 24, 1181–1190. <https://doi.org/10.1016/j.chembiol.2017.05.024>
- Cui, J., Zhu, Q., Zhang, H., Cianfrocco, M.A., Leschziner, A.E., and 2 others, 2017. Structure of Fam20A reveals a pseudokinase featuring a unique disulfide pattern and inverted ATP-binding. *Elife* 6. <https://doi.org/10.7554/eLife.23990>
- Cui, Q., Wang, J.-Q., Assaraf, Y.G., Ren, L., Gupta, P., and 4 others, 2018. Modulating ROS to overcome multidrug resistance in cancer. *Drug Resistance Updates* 41, 1–25. <https://doi.org/10.1016/j.drug.2018.11.001>
- Da Silva, C.G., Peters, G.J., Ossendorp, F., Cruz, L.J., 2017. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. *Cancer Chemother Pharmacol* 80, 881–894. <https://doi.org/10.1007/s00280-017-3427-1>
- Daelemans, D., Afonina, E., Nilsson, J., Werner, G., Kjems, J., and 3 others, 2002. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. *Proc Natl Acad Sci U S A* 99, 14440–14445. <https://doi.org/10.1073/pnas.212285299>
- Dalpiatz, A., Paganetto, G., Botti, G., Pavan, B., 2020. Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance? *Drug Discovery Today* 25, 1651–1667. <https://doi.org/10.1016/j.drudis.2020.07.023>
- D'Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J., 1994. Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A* 91, 4082–4085. <https://doi.org/10.1073/pnas.91.9.4082>
- Danhier, F., 2016. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? *Journal of Controlled Release* 244, 108–121. <https://doi.org/10.1016/j.jconrel.2016.11.015>
- Dansen, T.B., Burgering, B.M.T., 2008. Unravelling the tumor-suppressive functions of FOXO proteins. *Trends Cell Biol* 18, 421–429. <https://doi.org/10.1016/j.tcb.2008.07.004>
- Davies, B.R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., and 16 others, 2012. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. *Mol Cancer Ther* 11, 873–887. <https://doi.org/10.1158/1535-7163.MCT-11-0824-T>
- Dal Bo, De Mattia, E., Baboci, L., Mezzalana, S., Cecchin, E., Assaraf, Y.G., Toffoli, G., 2020. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. *Drug Resist Updat* 51, 100702. <https://doi.org/10.1016/j.drug.2020.100702>
- Dang, C.V., Reddy, E.P., Shokat, K.M., Soucek, L., 2017. Drugging the 'undruggable' cancer targets. *Nature Reviews Cancer* 17, 502–508. <https://www.nature.com/articles/nrc.2017.36>
- Davies, G., Lobanova, L., Dawicki, W., Groot, G., Gordon, J.R., and 3 others, 2017. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. *PLoS One* 12, e0187191. <https://doi.org/10.1371/journal.pone.0187191>
- Davis, E.J., Johnson, D.B., Sosman, J.A., Chandra, S., 2018. Melanoma: What do all the mutations mean?: Mutations in Melanoma. *Cancer* 124, 3490–3499. <https://doi.org/10.1002/cncr.31345>
- De Boo, S., Kopecka, J., Brusa, D., Gazzano, E., Matera, L., and 3 others, 2009. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. *Mol Cancer* 8, 108. <https://doi.org/10.1186/1476-4598-8-108>
- de Sousa e Melo, F., Kurtova, A.V., Harnoss, J.M., Kljavin, N., Hoeck, J.D., and 8 others, 2017. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. *Nature* 543, 676–680. <https://doi.org/10.1038/nature21713>
- Dean, M., Fojo, T., Bates, S., 2005. Tumour stem cells and drug resistance. *Nat Rev Cancer* 5, 275–284. <https://doi.org/10.1038/nrc1590>
- Deng, J., Wang, Y., Lei, J., Lei, W., Xiong, J.P., 2017. Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance. *Tumour Biol* 39, 101042831769755. <https://doi.org/10.1177/1010428317697553>
- Deng, Z., Yan, F., Jin, Q., Li, F., Wu, J., and 2 others, 2014. Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound. *Journal of Controlled Release* 174, 109–116. <https://doi.org/10.1016/j.jconrel.2013.11.018>
- Dhawan, N.S., Scopton, A.P., Dar, A.C., 2016. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. *Nature* 537, 112–116. <https://doi.org/10.1038/nature19327>
- Dinić, J., Efferth, T., Garcia-Sosa, A.T., Grahovac, J., Padròn, J.M., Pajeva, I., and 4 others, 2020. Repurposing old drugs to fight multidrug resistant cancers. *Drug Resist Updat* 52, 100713. <https://doi.org/10.1016/j.drug.2020.100713>
- Di Magno, L., Di Pastena, F., Puxeddu, M., La Regina, G., Coluccia, A., and 6 others, 2020. Sulfonamide Inhibitors of β -Catenin Signaling as Anticancer Agents with Different Output on c-MYC. *ChemMedChem* 15, 2264–2268. <https://doi.org/10.1002/cmdc.202000594>
- Dickmanns, A., Monecke, T., Ficner, R., 2015. Structural Basis of Targeting the Exportin CRM1 in Cancer. *Cells* 4, 538–568. <https://doi.org/10.3390/cells4030538>
- Diesendruck, Y.; Benhar, I., 2017. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges. *Drug Resist Updat* 30, 39–47. <https://doi.org/10.1016/j.drug.2017.02.001>
- Donahue, N.D., Acar, H., Wilhelm, S., 2019. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. *Advanced Drug Delivery Reviews* 143, 68–96. <https://doi.org/10.1016/j.addr.2019.04.008>
- Doroudian, M., O' Neill, A., Mac Loughlin, R., Prina-Mello, A., Volkov, Y., and 1 other, 2021. Nanotechnology in pulmonary medicine. *Current Opinion in Pharmacology* 56, 85–92. <https://doi.org/10.1016/j.coph.2020.11.002>
- Drews, J., 2000. *Drug Discovery: A Historical Perspective*. *Science* 287, 1960–1964. <https://doi.org/10.1126/science.287.5460.1960>
- D'souza, A.A., Shegokar, R., 2016. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. *Expert Opin Drug Deliv* 13, 1257–1275. <https://doi.org/10.1080/17425247.2016.1182485>
- Eijkelenboom, A., Burgering, B.M.T., 2013. FOXOs: signalling integrators for homeostasis maintenance. *Nat Rev Mol Cell Biol* 14, 83–97. <https://doi.org/10.1038/nrm3507>
- Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., and 1 other, 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development. *Proc Natl Acad Sci U S A* 94, 4273–4278. <https://doi.org/10.1073/pnas.94.9.4273>
- Emami, K.H., Nguyen, C., Ma, H., Kim, D.H., Jeong, K.W., and 8 others, 2004. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. *Proc Natl Acad Sci U S A* 101, 12682–12687. <https://doi.org/10.1073/pnas.0404875101>
- Engelberg, S., Netzer, E., Assaraf, Y.G., Livney, Y.D., 2019. Selective eradication of human non-small cell lung

- cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. *Cell Death Dis* 10, 702. <https://doi.org/10.1038/s41419-019-1870-0>
- Erin, N., Grahovac, J., Brozovic, A., Efferth, T., 2020. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. *Drug Resist Updat* 53, 100715. <https://doi.org/10.1016/j.drug.2020.100715>
- Etchin, J., Berezovskaya, A., Conway, A.S., Galinsky, I.A., Stone, R.M., and 7 others, 2017. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. *Leukemia* 31, 143–150. <https://doi.org/10.1038/leu.2016.145>
- Etchin, J., Sanda, T., Mansour, M.R., Kentsis, A., Montero, J., and 10 others, 2013. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. *Br J Haematol* 161, 117–127. <https://doi.org/10.1111/bjh.12231>
- Fam, S.Y., Chee, C.F., Yong, C.Y., Ho, K.L., Mariatulqabtiyah, A.R., and 1 other, 2020. Stealth Coating of Nanoparticles in Drug-Delivery Systems. *Nanomaterials* 10, 787. <https://doi.org/10.3390/nano10040787>
- Ferreira, B.I., Santos, B., Link, W., De Sousa-Coelho, A.L., 2021. Tribbles Pseudokinases in Colorectal Cancer. *Cancers* 13, 2825. <https://doi.org/10.3390/cancers13112825>
- Ferreira, B.I., Cautain, B., Grenho, I., Link, W., 2020a. Small Molecule Inhibitors of CRM1. *Front Pharmacol* 11, 625. <https://doi.org/10.3389/fphar.2020.00625>
- Ferreira, B.I., Cautain, B., Grenho, I., Link, W., 2020b. Small Molecule Inhibitors of CRM1. *Front Pharmacol* 11, 625. <https://doi.org/10.3389/fphar.2020.00625>
- Ferreira, B.I., Cautain, B., Grenho, I., Link, W., 2020c. Small Molecule Inhibitors of CRM1. *Front Pharmacol* 11, 625. <https://doi.org/10.3389/fphar.2020.00625>
- Ferreira, B.I., Hill, R., Link, W., 2015. Special Review: Caught in the Crosshairs Targeted Drugs and Personalized Medicine. *The Cancer Journal* 21, 441–447. <https://doi.org/10.1097/PPO.0000000000000161>
- Ferreira, B.I., Lie, M.K., Engelsens, A.S.T., Machado, S., Link, W., and 1 other, 2017. Adaptive mechanisms of resistance to anti-neoplastic agents. *Med. Chem. Commun.* 8, 53–66. <https://doi.org/10.1039/C6MD00394J>
- Fomerod, M., Ohno, M., Yoshida, M., Mattaj, I.W., 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. *Cell* 90, 1051–1060. [https://doi.org/10.1016/s0092-8674\(00\)80371-2](https://doi.org/10.1016/s0092-8674(00)80371-2)
- Foulkes, D.M., Byrne, D.P., Yeung, W., Shrestha, S., Bailey, F.P., and 8 others, 2018. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. *Sci Signal* 11. <https://doi.org/10.1126/scisignal.aat7951>
- Frezza, C., Martins, C.P., 2012. From tumor prevention to therapy: empowering p53 to fight back. *Drug Resist. Updat* 15, 258–267. <https://doi.org/10.1016/j.drug.2012.10.001>
- Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., and 2 others, 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. *Nature* 390, 308–311. <https://doi.org/10.1038/36894>
- Gao, D., Guo, X., Zhang, X., Chen, S., Wang, Y., and 5 others, 2020. Multifunctional phototheranostic nanomedicine for cancer imaging and treatment. *Materials Today Bio* 5, 100035. <https://doi.org/10.1016/j.mtbio.2019.100035>
- Gao, W., Lu, C., Chen, L., Keohavong, P., 2015. Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy. *J Thorac Oncol* 10, 815–825. <https://doi.org/10.1097/JTO.0000000000000485>
- Gao, L., Wu, Z.-X., Assaraf, Y.G., and 2 others, 2021. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. *Drug Resist Updat* 57, 100770. <https://doi.org/10.1016/j.drug.2021.100770>
- Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., LLeonart, M.E., 2020. Insights into new mechanisms and models of cancer stem cell multidrug resistance. *Seminars in Cancer Biology* 60, 166–180. <https://doi.org/10.1016/j.semcancer.2019.07.022>
- García-Santisteban, I., Arregi, I., Alonso-Mariño, M., Urbaneja, M.A., Garcia-Vallejo, J.J., and 2 others, 2016. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. *Cell Mol Life Sci* 73, 4685–4699. <https://doi.org/10.1007/s00018-016-2292-0>
- Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., and 3 others, 2006. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. *Mol Cancer Ther* 5, 1710–1722. <https://doi.org/10.1158/1535-7163.MCT-06-0289>
- Gashaw, I., Ellinghaus, P., Sommer, A., Asadullah, K., 2011. What makes a good drug target? *Drug Discovery Today* 16, 1037–1043. <https://doi.org/10.1016/j.drudis.2011.09.007>
- Gelderblom, H., Verweij, J., Nooter, K., Sparreboom, A., 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. *Eur J Cancer* 37, 1590–1598. [https://doi.org/10.1016/s0959-8049\(01\)00171-x](https://doi.org/10.1016/s0959-8049(01)00171-x)
- Giovannetti, E., Zucali, P.A., Assaraf, Y.G., Funel, N., Gemelli, M., Stark, M., and 9 others, 2017. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. *Ann Oncol* 28, 2725–2732. <https://pubmed.ncbi.nlm.nih.gov/28945836/>
- Gonen N., Assaraf, Y. G., 2012. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. *Drug Resist Updat* 15, 183–210. <https://www.sciencedirect.com/science/article/abs/pii/S1368764612000489?via%3Dihub>
- Gottesman, M.M., 2002. Mechanisms of Cancer Drug Resistance. *Annu. Rev. Med.* 53, 615–627. <https://doi.org/10.1146/annurev.med.53.082901.103929>
- Gounder, M.M., Zer, A., Tap, W.D., Salah, S., Dickson, M.A., and 20 others, 2016. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. *JCO* 34, 3166–3174. <https://doi.org/10.1200/JCO.2016.67.6346>
- Gray-Schopfer, V., Wellbrock, C., Marais, R., 2007. Melanoma biology and new targeted therapy. *Nature* 445, 851–857. <https://doi.org/10.1038/nature05661>
- Groenendijk, F.H., Bernards, R., 2014. Drug resistance to targeted therapies: Déjà vu all over again. *Molecular Oncology* 8, 1067–1083. <https://doi.org/10.1016/j.molonc.2014.05.004>
- Gu, Y.Z., Moran, S.M., Hogenesch, J.B., Wartman, L., Bradfield, C.A., 1998. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. *Gene Expr* 7, 205–213.
- Guillemette, C., 2003. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. *Pharmacogenomics J* 3, 136–158. <https://doi.org/10.1038/sj.tpj.6500171>
- Guo, J., Yu, Z., Das, M., Huang, L., 2020. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. *ACS Nano* 14, 5075–5089. <https://doi.org/10.1021/acsnano.0c01676>
- Gurunathan, S., Jeyaraj, M., Kang, M.-H., Kim, J.-H., 2020. Anticancer Properties of Platinum Nanoparticles and Retinoic Acid: Combination Therapy for the Treatment of Human Neuroblastoma Cancer. *IJMS* 21, 6792. <https://doi.org/10.3390/ijms21186792>
- Hagenbuchner, J., Ausserlechner, M.J., 2016. Targeting transcription factors by small compounds—Current strategies and future implications. *Biochemical Pharmacology* 107, 1–13. <https://doi.org/10.1016/j.bcp.2015.12.006>
- Hajduk, P.J., Huth, J.R., Tse, C., 2005. Predicting protein druggability. *Drug Discovery Today* 10, 1675–1682. [https://doi.org/10.1016/S1359-6446\(05\)03624-X](https://doi.org/10.1016/S1359-6446(05)03624-X)
- Hamamoto, T., Gunji, S., Tsuji, H., Beppu, T., 1983. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and

- characterization. *J Antibiot (Tokyo)* 36, 639–645. <https://doi.org/10.7164/antibiotics.36.639>
- Hanahan, D., Weinberg, R.A., 2011. Hallmarks of Cancer: The Next Generation. *Cell* 144, 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
- Hanahan, D., Weinberg, R.A., 2000. The Hallmarks of Cancer. *Cell* 100, 57–70. [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9)
- Hay, D.A., Fedorov, O., Martin, S., Singleton, D.C., Tallant, C., and 15 others, 2014. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. *J Am Chem Soc* 136, 9308–9319. <https://doi.org/10.1021/ja412434f>
- Hays, E., Bonavida, B., 2019. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. *Drug Resist Updat* 2019, 43, 10–28. <https://doi.org/10.1016/j.drug.2019.04.001>
- Henriques, V., Martins, T., Link, W., Ferreira, B.I., 2018. The Emerging Therapeutic Landscape of Advanced Melanoma. *CPD* 24, 549–558. <https://doi.org/10.2174/1381612824666180125093357>
- Heurtault, B., Saulnier, P., Pech, B., Proust, J.-E., Benoit, J.-P., 2002. A novel phase inversion-based process for the preparation of lipid nanocarriers. *Pharm Res* 19, 875–880. <https://doi.org/10.1023/a:1016121319668>
- Higashijima, Y., Tanaka, T., Nangaku, M., 2013. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. *Expert Opin Drug Discov* 8, 965–976. <https://doi.org/10.1517/17460441.2013.796358>
- Hildebrand, J.M., Tanzer, M.C., Lucet, I.S., Young, S.N., Spall, S.K., and 15 others, 2014. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. *Proc Natl Acad Sci U S A* 111, 15072–15077. <https://doi.org/10.1073/pnas.1408987111>
- Hill, R., Cautain, B., de Pedro, N., Link, W., 2014. Targeting nucleocytoplasmic transport in cancer therapy. *Oncotarget* 5, 11–28. <https://doi.org/10.18632/oncotarget.1457>
- Hirsch, H.A., Iliopoulos, D., Tschlis, P.N., Struhl, K., 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res* 69, 7507–7511. <https://doi.org/10.1158/0008-5472.CAN-09-2994>
- Hirsjarvi, S., Passirani, C., Benoit, J.-P., 2011. Passive and Active Tumour Targeting with Nanocarriers. *CDDT* 8, 188–196. <https://doi.org/10.2174/157016311796798991>
- Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., 2013. Cancer drug resistance: an evolving paradigm. *Nat Rev Cancer* 13, 714–726. <https://doi.org/10.1038/nrc3599>
- Hong, D.S., Marwan, G., Fakhri, M.D., Strickler, J.H., Desai, J., Durm, G.A., et al., 2020. KRAS^{G12C} inhibition with sotorasib in advanced solid tumors. *N Engl J Med* 383, 1207–1217. <https://www.nejm.org/doi/full/10.1056/NEJMoa1917239>
- Horn, H.F., Vousden, K.H., 2007. Coping with stress: multiple ways to activate p53. *Oncogene* 26, 1306–1316. <https://doi.org/10.1038/sj.onc.1210263>
- Hornsveld, M., Dansen, T.B., Derksen, P.W., Burgering, B.M.T., 2018. Re-evaluating the role of FOXOs in cancer. *Semin Cancer Biol* 50, 90–100. <https://doi.org/10.1016/j.semcancer.2017.11.017>
- Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., and 2 others, 2014. Drug Resistance in Cancer: An Overview. *Cancers* 6, 1769–1792. <https://doi.org/10.3390/cancers6031769>
- Hrckulak, D., Kolar, M., Strnad, H., Korinek, V., 2016. TCF/LEF Transcription Factors: An Update from the Internet Resources. *Cancers (Basel)* 8, 8. <https://doi.org/10.3390/cancers8070070>
- Huang, F.-Y., Lei, J., Sun, Y., Yan, F., Chen, B., and 6 others, 2018. Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes. *Oncolmmunology* 7, e1446720. <https://doi.org/10.1080/2162402X.2018.1446720>
- Huang, S.-M.A., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., and 31 others, F., 2009. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* 461, 614–620. <https://doi.org/10.1038/nature08356>
- Huerta-Yepe, S., Baritaki, S., Baay-Guzman, G., Hernandez-Luna, M.A., Hernandez-Cueto, A., and 2 others, 2013. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. *Nitric Oxide* 29, 17–24. <https://doi.org/10.1016/j.niox.2012.12.001>
- Ildas, P., Lepeltier, E., Jaouen, G., Passirani, C., 2021. Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors. *Cancers* 13, 2291. <https://doi.org/10.3390/cancers13102291>
- Ifergan, I., Meller, I., Issakov, J., Assaraf, Y.G., 2003. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. *Cancer* 98, 1958–1966. <https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.1741>
- Infante, P., Mori, M., Alfonsi, R., Ghirga, F., Aiello, F., Toscano, S., and 15 others, 2015. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. *EMBO J* 34, 200–217. <https://doi.org/10.15252/embj.201489213>
- Inoue, H., Kauffman, M., Shacham, S., Landesman, Y., Yang, J., and 2 others, 2013. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. *J Urol* 189, 2317–2326. <https://doi.org/10.1016/j.juro.2012.10.018>
- Isobe, M., Emanuel, B.S., Givol, D., Oren, M., Croce, C.M., 1986. Localization of gene for human p53 tumour antigen to band 17p13. *Nature* 320, 84–85. <https://doi.org/10.1038/320084a0>
- Iwasaki, Y., Kinoshita, M., Ikeda, K., 1989. Neurotrophic action of bombesin on ventral spinal cord in culture. *Int J Neurosci* 45, 195–198. <https://www.tandfonline.com/doi/abs/10.3109/00207458908986231>
- Izci, M., Maksoudian, C., Manshian, B.B., Soenen, S.J., 2021. The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors. *Chem. Rev.* 121, 1746–1803. <https://doi.org/10.1021/acs.chemrev.0c00779>
- Jacobsen, A.V., Murphy, J.M., 2017. The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases. *Biochem Soc Trans* 45, 665–681. <https://doi.org/10.1042/BST20160331>
- Jain, T., Nikolopoulou, E.A., Xu, Q., Qu, A., 2018. Hypoxia inducible factor as a therapeutic target for atherosclerosis. *Pharmacol Ther* 183, 22–33. <https://doi.org/10.1016/j.pharmthera.2017.09.003>
- Jaouen, G., Vessières, A., Top, S., 2015. Ferrocifen type anti cancer drugs. *Chem. Soc. Rev.* 44, 8802–8817. <https://doi.org/10.1039/C5CS00486A>
- Jha, B.K., Polyakova, I., Kessler, P., Dong, B., Dickerman, B., and 2 others, 2011. Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. *J Biol Chem* 286, 26319–26326. <https://doi.org/10.1074/jbc.M111.253443>
- Jimenez, L., Silva, A., Calissi, G., Grenho, I., Monteiro, R., Mayoral-Varo, V., and 7 others, 2021. Screening health-promoting compounds for their capacity to induce the activity of FOXO3. *J Gerontology, series A, glab265*. <https://doi.org/10.1093/gerona/glab265>
- Jorquera, P.A., Mathew, C., Pickens, J., Williams, C., Luczo, J.M., and 3 others, 2019. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro. *J Virol* 93. <https://doi.org/10.1128/JVI.01684-18>
- Jura, N., Shan, Y., Cao, X., Shaw, D.E., Kuriyan, J., 2009. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. *Proc Natl Acad Sci U S A* 106, 21608–21613. <https://doi.org/10.1073/pnas.0912101106>

- Kalbasi, A., Ribas, A., 2020. Tumour-intrinsic resistance to immune checkpoint blockade. *Nat Rev Immunol* 20, 25–39. <https://doi.org/10.1038/s41577-019-0218-4>
- Kamarudin, M.N.A., Sarker, M.M.R., Zhou, J.-R., Parhar, I., 2019. Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects. *J Exp Clin Cancer Res* 38, 491. <https://doi.org/10.1186/s13046-019-1495-2>
- Kathawala, R.J.; Gupta, P.; Ashby, C.R., Chen, Z.+S., 2015, The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. *Drug Resist Updat* 18, 1-17. <https://doi.org/10.1016/j.drup.2014.11.002>
- Kau, T.R., Schroeder, F., Ramaswamy, S., Wojciechowski, C.L., Zhao, J.J., and 4 others, 2003. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. *Cancer Cell* 4, 463–476. [https://doi.org/10.1016/s1535-6108\(03\)00303-9](https://doi.org/10.1016/s1535-6108(03)00303-9)
- Kaufman, Y.; Ifergan, I.; Rothem, L., Jansen, G., Assaraf, Y.G., 2006. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss. *Blood* 107, 3288-3294. <https://ashpublications.org/blood/article/107/8/3288/22247/>
- Kaur, G., Gupta, S.K., Singh, P., Ali, V., Kumar, V., Verma, M., 2020. Drug-metabolizing enzymes: role in drug resistance in cancer. *Clinical Transl Oncology* 22, 1667–1680. <https://link.springer.com/article/10.1007/s12094-020-02325-7>
- Keifer, J.A., Guttridge, D.C., Ashburner, B.P., Baldwin, A.S., 2001. Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity. *J Biol Chem* 276, 22382–22387. <https://doi.org/10.1074/jbc.M100938200>
- Khot, V.M., Salunkhe, A.B., Pricl, S., Bauer, J., Thorat, N.D., and 1 other, 2021. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. *Drug Discovery Today* 26, 724–739. <https://doi.org/10.1016/j.drudis.2020.12.016>
- Kim, M.K., Osada, T., Barry, W.T., Yang, X.Y., Freedman, J.A., Tsamis, K.A., Datto, M., Clary, B.M., Clay, T., Morse, M.A., et al. 2012, Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer. *Mol Cancer Ther*, 11, 1500-1509. <https://mct.aacrjournals.org/content/11/7/1500.short>
- Kim, J., Yung, B.C., Kim, W.J., Chen, X., 2017. Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. *J Control Release* 263, 223–230. <https://doi.org/10.1016/j.jconrel.2016.12.026>
- Kilil-Drori, A.J., Azoulay, L., Pollak, M.N., 2017. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? *Nat Rev Clin Oncol* 14, 85–99. <https://doi.org/10.1038/nrclinonc.2016.120>
- Kohno, K., Uchiyama, T., Niina, I., Wakasugi, T., Igarashi, T., and 5 others, 2005. Transcription factors and drug resistance. *European Journal of Cancer* 41, 2577–2586. <https://doi.org/10.1016/j.ejca.2005.08.007>
- Kojima, K., Kornblau, S.M., Ruvolo, V., Dilip, A., Duvvuri, S., and 11 others, 2013. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. *Blood* 121, 4166–4174. <https://doi.org/10.1182/blood-2012-08-447581>
- Kon E., Benhar, I., 2019. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. *Drug Resist Updat* 45, 13-29. <https://doi.org/10.1016/j.drup.2019.07.004>
- Kopecka, J., Trouillas, P., Gasparović, A.C., Gazzano, E., Assaraf, Y.G., Riganti, C., 2020. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. *Drug Resist Updat* 49, 100670. <https://doi.org/10.1016/j.drup.2019.100670>
- Koren, E., Fuchs, Y., 2016. The bad seed: Cancer stem cells in tumor development and resistance. *Drug Resist Updat* 28, 1-12. <https://doi.org/10.1016/j.drup.2016.06.006>
- Kozar, I., Margue, C., Rothengatter, S., Haan, C., Kreis, S., 2019. Many ways to resistance: How melanoma cells evade targeted therapies. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* 1871, 313–322. <https://doi.org/10.1016/j.bbcan.2019.02.002>
- Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E.P., and 3 others, 1999. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. *Proc Natl Acad Sci U S A* 96, 9112–9117. <https://doi.org/10.1073/pnas.96.16.9112>
- Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E.P., Yoneda, Y., and 3 others, 1998. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. *Exp Cell Res* 242, 540–547. <https://doi.org/10.1006/excr.1998.4136>
- Kumar, S., Kushwaha, P.P., Gupta, S., 2019. Emerging targets in cancer drug resistance. *Cancer Drug Resistance* 2, 161–177. <https://doi.org/10.20517/cdr.2018.27>
- Kung, A.L., Zabludoff, S.D., France, D.S., Freedman, S.J., Tanner, E.A., and 12 others, 2004. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. *Cancer Cell* 6, 33–43. <https://doi.org/10.1016/j.ccr.2004.06.009>
- Kung, J.E., Jura, N., 2019. Prospects for pharmacological targeting of pseudokinases. *Nat Rev Drug Discov* 18, 501–526. <https://doi.org/10.1038/s41573-019-0018-3>
- Kung, J.E., Jura, N., 2016. Structural Basis for the Non-catalytic Functions of Protein Kinases. *Structure* 24, 7–24. <https://doi.org/10.1016/j.str.2015.10.020>
- Lainé, A.-L., Clavreul, A., Rousseau, A., Tétaud, C., Vessieres, A., and 7 others, 2014. Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules. *Nanomedicine: Nanotechnology, Biology and Medicine* 10, 1667–1677. <https://doi.org/10.1016/j.nano.2014.05.002>
- Lang, I., Füllsack, S., Wyzgol, A., Fick, A., Trebing, J., and 4 others, 2016. Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells. *J Biol Chem* 291, 5022–5037. <https://doi.org/10.1074/jbc.M115.683946>
- Lapalombella, R., Sun, Q., Williams, K., Tangeman, L., Jha, S., and 18 others, 2012. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. *Blood* 120, 4621–4634. <https://doi.org/10.1182/blood-2012-05-429506>
- Lapatinib, 2015. BC Cancer Agency Cancer Drug Manual.
- Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., and 14 others, 2013. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. *Cancer Res* 73, 3132–3144. <https://doi.org/10.1158/0008-5472.CAN-12-4562>
- Le Saux, S., Aarrass, H., Lai-Kee-Him, J., Bron, P., Armengaud, J., and 9 others, 2020. Post-production modifications of murine mesenchymal stem cell (mMSC) derived extracellular vesicles (EVs) and impact on their cellular interaction. *Biomaterials* 231, 119675. <https://doi.org/10.1016/j.biomaterials.2019.119675>
- Lee, H.L., Hwang, S.C., Nah, J.W., Kim, J., Cha, B., and 2 others, 2018. Redox- and pH-Responsive Nanoparticles Release Piperlongumine in a Stimuli-Sensitive Manner to Inhibit Pulmonary Metastasis of Colorectal Carcinoma Cells. *Journal of Pharmaceutical Sciences* 107, 2702–2712. <https://doi.org/10.1016/j.xphs.2018.06.011>
- Leonetti, A., Wever, B., Mazzaschi, G., Assaraf, Y.G., Rolfo, G., Quaini, F., Tiseo, M., Giovannetti, E., 2019. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. *Drug Resist Updat* 46, 100644. <https://doi.org/10.1016/j.drup.2019.100644>
- Lepeltier, E., Rijo, P., Rizzolio, F., Popovtzer, R., Petrikaitė, V., and 2 others, 2020. Nanomedicine to target multidrug resistant tumors. *Drug Resistance Updates* 52, 100704. <https://doi.org/10.1016/j.drup.2020.100704>
- Levin, M., Stark, M., Ofran, Y., Assaraf, Y.G., 2021. Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance. *Cancer Cell Int*, 21, 53. <https://cancerjournal.biomedcentral.com/articles/10.1186/s12935-021-01746-w>
- Levit, S.L., Yang, H., Tang, C., 2020. Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of

- Paclitaxel and Lapatinib via Flash NanoPrecipitation. *Nanomaterials* 10, 561. <https://doi.org/10.3390/nano10030561>
- Li, W., Zhang, H., Assaraf, Y.G., Zhao, K., Xu, X., Xie, J., 2016. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. *Drug Resist Updat* 27, 14-29. <https://doi.org/10.1016/j.drug.2016.05.001>
- Li, S., Yi, M., Dong, B., Jiao, Y., Luo, S., and 1 other, 2020. The roles of exosomes in cancer drug resistance and its therapeutic application. *Clinical and Translational Medicine* 10. <https://doi.org/10.1002/ctm2.257>
- Li, Z., You, Q., Zhang, X., 2019. Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications. *J Med Chem* 62, 5725–5749. <https://doi.org/10.1021/acs.jmedchem.8b01596>
- Link, W., 2018. Knowledge-based drug discovery intensifies private appropriation of publicly financed research. *The Lancet Oncology* 19, 1017–1018. [https://doi.org/10.1016/S1470-2045\(18\)30437-6](https://doi.org/10.1016/S1470-2045(18)30437-6)
- Link, W., Fernandez-Marcos, P.J., 2017. FOXO transcription factors at the interface of metabolism and cancer: FOXO transcription factors. *Int. J. Cancer* 141, 2379–2391. <https://doi.org/10.1002/ijc.30840>
- Link, W., Oyarzabal, J., Serelde, B.G., Albarran, M.I., Rabal, O., and 14 others, 2009. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. *J Biol Chem* 284, 28392–28400. <https://doi.org/10.1074/jbc.M109.038984>
- Lisek, K., Campaner, E., Ciani, Y., Walerych, D., Del Sal, G., 2018. Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. *Oncotarget* 9, 20508–20523. <https://doi.org/10.18632/oncotarget.24974>
- Liu, G., Lovell, J.F., Zhang, L., Zhang, Y., 2020. Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment. *IJMS* 21, 6380. <https://doi.org/10.3390/ijms21176380>
- Liu, J., Pan, S., Hsieh, M.H., Ng, N., Sun, F., and 30 others, 2013. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proc Natl Acad Sci U S A* 110, 20224–20229. <https://doi.org/10.1073/pnas.1314239110>
- Liu, T., Zhang, L., Joo, D., Sun, S.-C., 2017. NF- κ B signaling in inflammation. *Signal Transduct Target Ther* 2. <https://doi.org/10.1038/sigtrans.2017.23>
- Liu, X., Jiang, J., Chang, C.H., Liao, Y., Lodico, J.J., and 9 others, 2021. Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. *Small* 17, 2005993. <https://doi.org/10.1002/sml.202005993>
- Liu, X., Niu, M., Xu, X., Cai, W., Zeng, L., and 3 others, 2014. CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin. *J Pharmacol Sci* 124, 486–493. <https://doi.org/10.1254/jphs.13240fp>
- Liu, Y., Qiao, L., Zhang, S., Wan, G., Chen, B., and 3 others, 2018. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. *Acta Biomaterialia* 66, 310–324. <https://doi.org/10.1016/j.actbio.2017.11.010>
- Livney, Y.D., Assaraf, Y.G., 2013. Rationally designed nanovehicles to overcome cancer chemoresistance. *Advanced Drug Delivery Reviews* 65, 1716–1730. <https://doi.org/10.1016/j.addr.2013.08.006>
- Locksley, R.M., Killeen, N., Lenardo, M.J., 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. *Cell* 104, 487–501. [https://doi.org/10.1016/s0092-8674\(01\)00237-9](https://doi.org/10.1016/s0092-8674(01)00237-9)
- Lord, C.J., Ashworth, A., 2012. The DNA damage response and cancer therapy. *Nature* 481, 287–294. <https://doi.org/10.1038/nature10760>
- Luke, J.J., Flaherty, K.T., Ribas, A., Long, G.V., 2017. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol* 14, 463–482. <https://doi.org/10.1038/nrclinonc.2017.43>
- Luke, J.J., Hodi, F.S., 2013. Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. *The Oncologist* 18, 717–725. <https://doi.org/10.1634/theoncologist.2012-0391>
- Ma, B., Marcotte, D., Paramasivam, M., Michelsen, K., Wang, T., and 8 others, 2016. ATP-Competitive MLKL Binders Have No Functional Impact on Necroptosis. *PLoS One* 11, e0165983. <https://doi.org/10.1371/journal.pone.0165983>
- Machado, S., Silva, A., De Sousa-Coelho, A.L., Duarte, I., Grenho, I., Santos, B., and 6 others, 2020. Harmine and piperlongumine revert TRIB2-mediated drug resistance. *Cancers* 12, 3689. <https://doi.org/10.3390/cancers12123689>
- MacKay, Andrew.J., Chen, M., McDaniel, J.R., Liu, W., and 2 others, 2009. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. *Nature Mater* 8, 993–999. <https://doi.org/10.1038/nmat2569>
- Maeda, H., 2021. The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery—Personal Remarks and Future Prospects. *JPM* 11, 229. <https://doi.org/10.3390/jpm11030229>
- Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S., 2002. The protein kinase complement of the human genome. *Science* 298, 1912–1934. <https://doi.org/10.1126/science.1075762>
- Mantovani, F., Collavin, L., Del Sal, G., 2019. Mutant p53 as a guardian of the cancer cell. *Cell Death Differ* 26, 199–212. <https://doi.org/10.1038/s41418-018-0246-9>
- Marjaneh, R.M., Khazaei, M., Ferns, G.A., Avan, A., Aghaee-Bakhtiari, S.H., 2019. The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms. *J Cell Physiol* 234, 2306–2316. <https://doi.org/10.1002/jcp.27221>
- Martins, R., Lithgow, G.J., Link, W., 2016. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. *Aging Cell* 15, 196–207. <https://doi.org/10.1111/acer.12427>
- Martins, C.P., Brown-Swigart, L., Evan, G.I., 2006. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors. *Cell* 127, 1323–1334. <https://doi.org/10.1016/j.cell.2006.12.007>
- Mashouri, L., Yousefi, H., Aref, A.R., Ahadi, A.M., Molaei, F., and 1 other, 2019. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. *Mol Cancer* 18, 75. <https://doi.org/10.1186/s12943-019-0991-5>
- Masoud, G.N., Li, W., 2015. HIF-1 α pathway: role, regulation and intervention for cancer therapy. *Acta Pharm Sin B* 5, 378–389. <https://doi.org/10.1016/j.apsb.2015.05.007>
- Mastria, E.M., Cai, L.Y., Kan, M.J., Li, X., Schaal, J.L., and 5 others, 2018. Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. *Journal of Controlled Release* 269, 364–373. <https://doi.org/10.1016/j.jconrel.2017.11.021>
- Mayoral-Varo, V., Jiménez, L., Link, W., 2021. The Critical Role of TRIB2 in Cancer and Therapy Resistance. *Cancers* 13, 2701. <https://doi.org/10.3390/cancers13112701>
- Miele, E., Spinelli, G.P., Miele, E., Tomao, F., Tomao, S., 2009. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. *Int J Nanomedicine* 4, 99–105. <https://doi.org/10.2147/ijn.s3061>
- Mirza, Z., Karim, S., 2021. Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. *Seminars in Cancer Biology* 69, 226–237. <https://doi.org/10.1016/j.semcancer.2019.10.020>
- Mobasser, R., Karimi, M., Tian, L., Naderi-Manesh, H., Ramakrishna, S., 2017. Hydrophobic lapatinib encapsulated dextran-chitosan nanoparticles using a toxic solvent free method: fabrication, release property & in vitro anti-cancer activity. *Materials Science and Engineering: C* 74, 413–421. <https://doi.org/10.1016/j.msec.2016.12.027>
- Mohammad, R.M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., and 34 others, 2015. Broad targeting of resistance to apoptosis in cancer. *Semin Cancer Biol* 35 Suppl, S78–S103. <https://doi.org/10.1016/j.semcancer.2015.03.001>
- Moore, A.R., Rosenberg, S.C., McCormick, F., Malek, S., 2020. RAS-targeted therapies: is the undruggable drugged?

- Nature Reviews Drug Discovery 19, 533–552. <https://www.nature.com/articles/s41573-020-0068-6>
- Moraru, C., Mincea, M., Menghiu, G., Ostafe, V., 2020. Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications. *Molecules* 25, 4758. <https://doi.org/10.3390/molecules25204758>
- Mudduluru, G., Walther, W., Kobelt, D., Dahlmann, M., Treese, C., Assaraf, Y.G., Stein, U., 2016 Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. *Drug Resist Updat* 26, 10–27. <https://doi.org/10.1016/j.drug.2016.03.002>
- Murakami, N., Ye, Y., Kawanishi, M., Aoki, S., Kudo, N., and 4 others, 2002. New Rev-transport inhibitor with anti-HIV activity from *Valerianae Radix*. *Bioorg Med Chem Lett* 12, 2807–2810. [https://doi.org/10.1016/s0960-894x\(02\)00624-8](https://doi.org/10.1016/s0960-894x(02)00624-8)
- Murphy, J.M., Zhang, Q., Young, S.N., Reese, M.L., Bailey, F.P., and 19 others, 2014. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. *Biochem J* 457, 323–334. <https://doi.org/10.1042/BJ20131174>
- Narayanan, S.; Cai, C.-Y., Assaraf, Y.G., Guo, H.-Q., Cui, Q., Wei, L., and 3 others, 2020, Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. *Drug Resist Updat* 48, 100663. <https://doi.org/10.1016/j.drug.2019.100663>
- Nayak, P.P., S., N., Narayanan, A., Badekila, A.K., Kini, S., 2021. Nanomedicine in Cancer Clinics: Are We There Yet? *Curr Pathobiol Rep* 9, 43–55. <https://doi.org/10.1007/s40139-021-00220-6>
- Neklesa, T.K., Tae, H.S., Schneekloth, A.R., Stulberg, M.J., Corson, T.W., and 4 others, 2011. Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. *Nat Chem Biol* 7, 538–543. <https://doi.org/10.1038/nchembio.597>
- Newlands, E.S., Rustin, G.J., Brampton, M.H., 1996. Phase I trial of elactocin. *Br J Cancer* 74, 648–649. <https://doi.org/10.1038/bjc.1996.415>
- Niu, M., Chong, Y., Han, Y., Liu, X., 2015a. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. *Cancer Biol Ther* 16, 1110–1118. <https://doi.org/10.1080/15384047.2015.1047569>
- Niu, M., Xu, X., Shen, Y., Yao, Y., Qiao, J., and 4 others, 2015b. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity. *Chem Biol Interact* 237, 66–72. <https://doi.org/10.1016/j.cbi.2015.05.016>
- Nguyen, K.T., Holloway, M.P., Altura, R.A., 2012. The CRM1 nuclear export protein in normal development and disease. *Int J Biochem Mol Biol* 3, 137–151. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388738/>
- Noske, A., Weichert, W., Niesporek, S., Röske, A., Buckendahl, A.-C., and 4 others, 2008. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. *Cancer* 112, 1733–1743. <https://doi.org/10.1002/cncr.23354>
- O'Hare, T., Eide, C.A., Deininger, M.W.N., 2007. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. *Blood* 110, 2242–2249. <https://doi.org/10.1182/blood-2007-03-066936>
- Olenyuk, B.Z., Zhang, G.-J., Klco, J.M., Nickols, N.G., Kaelin, W.G., and 1 other, 2004. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. *Proc Natl Acad Sci U S A* 101, 16768–16773. <https://doi.org/10.1073/pnas.0407617101>
- Orlando, I.M.C., Laffleur, V.N., Storti, F., Spielmann, P., Crowther, L., Santambrogio, S., and 4 others, 2020. Distal and proximal hypoxia response elements cooperate to regulate organ-specific erythropoietin gene expression. *Haematologica* 105, 2774–2784. <https://doi.org/10.3324/haematol.2019.236406>
- Ozer, I., Tomak, A., Zareie, H.M., Baran, Y., Bulmus, V., 2017. Effect of Molecular Architecture on Cell Interactions and Stealth Properties of PEG. *Biomacromolecules* 18, 2699–2710. <https://doi.org/10.1021/acs.biomac.7b00443>
- Paik, J.-H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., and 11 others, 2007. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. *Cell* 128, 309–323. <https://doi.org/10.1016/j.cell.2006.12.029>
- Paraiso, K.H.T., Xiang, Y., Rebecca, V.W., Abel, E.V., Chen, Y.A., and 11 others, 2011. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. *Cancer Res* 71, 2750–2760. <https://doi.org/10.1158/0008-5472.CAN-10-2954>
- Park, S.-H., Seong, M.-A., Lee, H.-Y., 2016. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. *Oncotarget* 7, 8184–8199. <https://doi.org/10.18632/oncotarget.6945>
- Pautu, V., Lepeltier, E., Mellinger, A., Riou, J., Debuigne, A., and 3 others, 2021. pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization. *Cancers* 13, 2028. <https://doi.org/10.3390/cancers13092028>
- Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., and 1 other, 2007. Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotech* 2, 751–760. <https://doi.org/10.1038/nnano.2007.387>
- Pérez-Herrero, E., Fernández-Medarde, A., 2015. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. *European Journal of Pharmaceutics and Biopharmaceutics* 93, 52–79. <https://doi.org/10.1016/j.ejpb.2015.03.018>
- Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmiento-Ribeiro, A.B., García-Aranda, M., and 1 other, 2020. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. *Drug Resistance Updates* 53, 100718. <https://doi.org/10.1016/j.drug.2020.100718>
- Petitjean, A., Achatz, M.I.W., Borresen-Dale, A.L., Hainaut, P., Olivier, M., 2007. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene* 26, 2157–2165. <https://doi.org/10.1038/sj.onc.1210302>
- Pinhassi, R.I., Assraf, Y.G., Farber, S., Stark, M., Ickowicz, D., Drori, S., and 2 others, 2010. Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. *Biomacromolecules* 11, 294–303. <https://doi.org/10.1021/bm900853z>
- Puimège, L., Libert, C., Van Hauwermeiren, F., 2014. Regulation and dysregulation of tumor necrosis factor receptor-1. *Cytokine Growth Factor Rev* 25, 285–300. <https://doi.org/10.1016/j.cytogfr.2014.03.004>
- Qu, C., Zhang, W., Zheng, G., Zhang, Z., Yin, J., and 1 other, 2014. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. *Mol Cell Biochem* 386, 63–71. <https://doi.org/10.1007/s11010-013-1845-x>
- Ranganathan, P., Yu, X., Na, C., Santhanam, R., Shacham, S., and 8 others, 2012. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. *Blood* 120, 1765–1773. <https://doi.org/10.1182/blood-2012-04-423160>
- Reiterer, V., Eysers, P.A., Farhan, H., 2014. Day of the dead: pseudokinases and pseudophosphatases in physiology and disease. *Trends Cell Biol* 24, 489–505. <https://doi.org/10.1016/j.tcb.2014.03.008>
- Resnier, P., Galopin, N., Sibiril, Y., Clavreul, A., Cayon, J., and 7 others, C., 2017. Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse. *Pharmacological Research* 126, 54–65. <https://doi.org/10.1016/j.phrs.2017.01.031>
- Richmond, V., Michelini, F.M., Bueno, C.A., Alché, L.E., Ramirez, J.A., 2015. Small Molecules as Anti-TNF Drugs. *Curr Med Chem* 22, 2920–2942. <https://doi.org/10.2174/0929867322666150729115553>
- Riganti, C., Contino, M., 2019. New Strategies to Overcome Resistance to Chemotherapy and Immune System

- in Cancer. *Int. J. Mol. Sci.* 20, 4783. <https://doi.org/10.3390/ijms20194783>
- Robey, R.W., Pluchino, K.M., Hall, M.D., Fojo, A.T., Bates, S.E., and 1 other, 2018. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat Rev Cancer* 18, 452–464. <https://doi.org/10.1038/s41568-018-0005-8>
- Rochat, B., 2005. Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance: Focus on Tamoxifen, Paclitaxel and Imatinib Metabolism. *Clinical Pharmacokinetics* 44, 349–366. <https://doi.org/10.2165/00003088-200544040-00002>
- Roger, M., Clavreul, A., Huynh, N.T., Passirani, C., Schiller, P., and 3 others, 2012. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. *International Journal of Pharmaceutics* 423, 63–68. <https://doi.org/10.1016/j.ijpharm.2011.04.058>
- Roger, M., Clavreul, A., Venier-Julienne, M.-C., Passirani, C., Montero-Menei, C., and 1 other, 2011. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. *Biomaterials* 32, 2106–2116. <https://doi.org/10.1016/j.biomaterials.2010.11.056>
- Rothem, L., Ifergam, I., Kaufman, Y., Priest, D.G., Jansen, G., Assaraf, Y.G., 2002. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. *Biochem J* 367, 741–750. <https://pubmed.ncbi.nlm.nih.gov/12139489/>
- Rothem, L., Aronheim, A., Assaraf, Y.G., 2003. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. *J Biol Chem* 278, 8935. [https://www.jbc.org/article/S0021-9258\(19\)71259-9](https://www.jbc.org/article/S0021-9258(19)71259-9)
- Rothem, L., Stark, M., Kaufman, Y., Mayo, L., Assaraf, Y.G. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. *J. Biol Chem* 279(, 374-384. <https://pubmed.ncbi.nlm.nih.gov/14551190/>
- Rowland, A., Miners, J.O., Mackenzie, P.I., 2013. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. *Int J Biochem Cell Biol* 45, 1121–1132. <https://doi.org/10.1016/j.biocel.2013.02.019>
- Ruiz-Saenz, A., Sandhu, M., Carrasco, Y., Maglathlin, R.L., Taunton, J., and 1 other, 2015. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. *Oncogene* 34, 5288–5294. <https://doi.org/10.1038/ncr.2014.455>
- Sakakibara, K., Saito, N., Sato, T., Suzuki, A., Hasegawa, Y., and 5 others, 2011. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. *Blood* 118, 3922–3931. <https://doi.org/10.1182/blood-2011-01-333138>
- Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., Caro, J., 2002. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. *Mol Cell Biol* 22, 2984–2992. <https://doi.org/10.1128/MCB.22.9.2984-2992.2002>
- Santoro, R., Carbone, C., Piro, G., Chiao, P.J., Melisi, D., 2017. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. *Drug Resist Updat* 33-35, 36-42. <https://doi.org/10.1016/j.drug.2017.10.004>
- Saraei, P., Asadi, I., Kakar, M.A., Moradi-Kor, N., 2019. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. *Cancer Manag Res* 11, 3295–3313. <https://doi.org/10.2147/CMAR.S200059>
- Scales, S.J., de Sauvage, F.J., 2009. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. *Trends Pharmacol Sci* 30, 303-312. <https://doi.org/10.1016/j.tips.2009.03.007>
- Schmidt, J., Braggio, E., Kortuem, K.M., Egan, J.B., Zhu, Y.X., and 10 others, 2013. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. *Leukemia* 27, 2357–2365. <https://doi.org/10.1038/leu.2013.172>
- Schwartz, D.L., Bankson, J.A., Lemos, R., Lai, S.Y., Thittai, A.K., and 5 others, 2010. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. *Mol Cancer Ther* 9, 2057–2067. <https://doi.org/10.1158/1535-7163.MCT-09-0768>
- Sebio, A., Kahn, M., Lenz, H.-J., 2014. The potential of targeting Wnt/β-catenin in colon cancer. *Expert Opin Ther Targets* 18, 611–615. <https://doi.org/10.1517/14728222.2014.906580>
- Semenza, G.L., 2002. Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1 alpha with p300 and CBP. *Proc Natl Acad Sci U S A* 99, 11570–11572. <https://doi.org/10.1073/pnas.192442299>
- Serra, V., Markman, B., Scaltriti, M., Eichhorn, P.J.A., Valero, V., and 10 others, 2008. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. *Cancer Res* 68, 8022–8030. <https://doi.org/10.1158/0008-5472.CAN-08-1385>
- Shafiei-Irannejad, V., Samadi, N., Salehi, R., Yousefi, B., Rahimi, M., and 2 others, 2018. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles. *Pharm Res* 35, 119. <https://doi.org/10.1007/s11095-018-2404-7>
- Shahar, N., Larish, S., 2020. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. *Drug Resist Updat* 52, 100712. <https://doi.org/10.1016/j.drug.2020.100712>
- Shang, S., Hua, F., Hu, Z.-W., 2017. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. *Oncotarget* 8, 33972–33989. <https://doi.org/10.18632/oncotarget.15687>
- Shapira, A., Livney, Y.D., Broxterman, H.J., Assaraf, Y.G., 2011. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. *Drug Resistance Updates* 14, 150–163. <https://doi.org/10.1016/j.drug.2011.01.003>
- Sharifzad, F., Ghavami, S., Verdi, J., Mardpour, S., Sisakht, M.M., Azizi, Z., and 5 others, 2019. Glioblastoma cancer stem cell biology: Potential therapeutic targets. *Drug Resist Updat* 42, 35-45. <https://doi.org/10.1016/j.drug.2018.03.003>
- Sharkey, C.C., Li, J., Roy, S., Wu, Q., King, M.R., 2016. Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy. *Technology* 04, 60–69. <https://doi.org/10.1142/S2339547816500011>
- Sharma, P., Allison, J.P., 2015. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. *Cell* 161, 205–214. <https://doi.org/10.1016/j.cell.2015.03.030>
- Shaw, A.S., Kornev, A.P., Hu, J., Ahuja, L.G., Taylor, S.S., 2014. Kinases and pseudokinases: lessons from RAF. *Mol Cell Biol* 34, 1538–1546. <https://doi.org/10.1128/MCB.00057-14>
- Shen, A., Wang, Y., Zhao, Y., Zou, L., Sun, L., and 1 other, 2009. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. *Neurosurgery* 65, 153–159; discussion 159-160. <https://doi.org/10.1227/01.NEU.0000348550.47441.4B>
- Shibue, T., Weinberg, R.A., 2017. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat Rev Clin Oncol* 14, 611–629. <https://doi.org/10.1038/nrclinonc.2017.44>
- Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., and 5 others, 2017. Visualization and targeting of LGR5+ human colon cancer stem cells. *Nature* 545, 187–192. <https://doi.org/10.1038/nature22081>
- Singh, R., Fazal, Z., Freemantle, S.J., Spinella, M.J., 2019. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors. *Cancer Drug Resist* 2, 580–594. <https://doi.org/10.20517/cdr.2019.19>

- Song, Y., Buchwald, P., 2015. TNF superfamily protein-protein interactions: feasibility of small-molecule modulation. *Curr Drug Targets* 16, 393–408. <https://doi.org/10.2174/1389450116666150223115628>
- Stathopoulos, G.P., Boulikas, T., 2012. Lipoplatin Formulation Review Article. *Journal of Drug Delivery* 2012, 1–10. <https://doi.org/10.1155/2012/581363>
- Statsuk, A.V., Maly, D.J., Seeliger, M.A., Fabian, M.A., Biggs, W.H., and 4 others, 2008. Tuning a three-component reaction for trapping kinase substrate complexes. *J Am Chem Soc* 130, 17568–17574. <https://doi.org/10.1021/ja807066f>
- Stein, S.J., Mack, E.A., Rome, K.S., Pear, W.S., 2015. Tribbles in normal and malignant haematopoiesis. *Biochemical Society Transactions* 43, 1112–1115. <https://doi.org/10.1042/BST20150117>
- Stiewe, T., Haran, T.E., 2018. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. *Drug Resist Updat* 38, 27–43. <https://doi.org/10.1016/j.drup.2018.05.001>
- Stinchcombe, T.E., 2007. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL[®]-free formulation of paclitaxel. *Nanomedicine* 2, 415–423. <https://doi.org/10.2217/17435889.2.4.415>
- Stiewe, T., Haran, T.E., 2018. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. *Drug Resist Updat* 38, 27–43. <https://doi.org/10.1016/j.drup.2018.05.001>
- Su, Y., Simmen, R.C.M., 2009. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. *Carcinogenesis* 30, 331–339. <https://doi.org/10.1093/carcin/bgn279>
- Sun, Q., Carrasco, Y.P., Hu, Y., Guo, X., Mirzaei, H., and 2 others, 2013. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. *Proc Natl Acad Sci U S A* 110, 1303–1308. <https://doi.org/10.1073/pnas.1217203110>
- Sun, Q., Chen, X., Zhou, Q., Burstein, E., Yang, S., and 1 other, 2016. Inhibiting cancer cell hallmark features through nuclear export inhibition. *Signal Transduct Target Ther* 1, 16010. <https://doi.org/10.1038/sigtrans.2016.10>
- Swetha, K.L., Roy, A., 2018. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. *Drug Deliv. and Transl. Res.* 8, 1508–1526. <https://doi.org/10.1007/s13346-018-0578-5>
- Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M.Y., and 19 others, 2014. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. *Leukemia* 28, 155–165. <https://doi.org/10.1038/leu.2013.115>
- Takada, K., Zhu, D., Bird, G.H., Sukhdeo, K., Zhao, J.-J., and 12 others, 2012. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. *Sci Transl Med* 4, 148ra117. <https://doi.org/10.1126/scitranslmed.3003808>
- Terenzi, A., Pirker, C., Keppler, B.K., Berger, W., 2016. Anticancer metal drugs and immunogenic cell death. *J Inorg Biochem* 165, 71–79. <https://doi.org/10.1016/j.jinorgbio.2016.06.021>
- Thorne, C.A., Hanson, A.J., Schneider, J., Tahinci, E., Orton, D., and 14 others, 2010. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. *Nat Chem Biol* 6, 829–836. <https://doi.org/10.1038/nchembio.453>
- Tian, W., Chen, C., Lei, X., Zhao, J., Liang, J., 2018. CASTp 3.0: computed atlas of surface topography of proteins. *Nucleic Acids Res* 46, W363–W367. <https://doi.org/10.1093/nar/gky473>
- Top, S., Vessières, A., Leclercq, G., Quivy, J., Tang, J., and 3 others, 2003. Synthesis, Biochemical Properties and Molecular Modelling Studies of Organometallic Specific Estrogen Receptor Modulators (SERMs), the Ferrocifens and Hydroxyferrocifens: Evidence for an Antiproliferative Effect of Hydroxyferrocifens on both Hormone-Dependent and Hormone-Independent Breast Cancer Cell Lines. *Chem. Eur. J.* 9, 5223–5236. <https://doi.org/10.1002/chem.200305024>
- Topin-Ruiz, S., Mellinger, A., Lepeltier, E., Bourreau, C., Fouillet, J., and 5 others, 2021. p722 ferrocifen loaded lipid nanocapsules improve survival of murine xenografted-melanoma via a potentiation of apoptosis and an activation of CD8+ T lymphocytes. *International Journal of Pharmaceutics* 593, 120111. <https://doi.org/10.1016/j.ijpharm.2020.120111>
- Townsend, D.M., Tew, K.D., 2003. The role of glutathione-S-transferase in anti-cancer drug resistance. *Oncogene* 22, 7369–7375. <https://doi.org/10.1038/sj.onc.1206940>
- Tung, M.-C., Lin, P.-L., Wang, Y.-C., He, T.-Y., Lee, M.-C., and 3 others, 2015. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. *Oncotarget* 6, 41692–41705. <https://doi.org/10.18632/oncotarget.6150>
- Turner, J.G., Dawson, J., Sullivan, D.M., 2012. Nuclear export of proteins and drug resistance in cancer. *Biochem Pharmacol* 83, 1021–1032. <https://doi.org/10.1016/j.bcp.2011.12.016>
- Turner, J.G., Sullivan, D.M., 2008. CRM1-mediated nuclear export of proteins and drug resistance in cancer. *Curr Med Chem* 15, 2648–2655. <https://doi.org/10.2174/092986708786242859>
- Turner, N.C., Reis-Filho, J.S., 2012. Genetic heterogeneity and cancer drug resistance. *The Lancet Oncology* 13, e178–e185. [https://doi.org/10.1016/S1470-2045\(11\)70335-7](https://doi.org/10.1016/S1470-2045(11)70335-7)
- Tuynman, J.B., Vermeulen, L., Boon, E.M., Kemper, K., Zwinderman, A.H., and 2 others, 2008. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. *Cancer Res* 68, 1213–1220. <https://doi.org/10.1158/0008-5472.CAN-07-5172>
- Ugurel, S., Paschen, A., Becker, J.C., 2013. Dacarbazine in Melanoma: From a Chemotherapeutic Drug to an Immunomodulating Agent. *Journal of Investigative Dermatology* 133, 289–292. <https://doi.org/10.1038/jid.2012.341>
- van der Horst, A., Burgering, B.M.T., 2007. Stressing the role of FoxO proteins in lifespan and disease. *Nat Rev Mol Cell Biol* 8, 440–450. <https://doi.org/10.1038/nrm2190>
- van der Watt, P.J., Maske, C.P., Hendricks, D.T., Parker, M.I., Denny, L., and 3 others, 2009. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. *Int J Cancer* 124, 1829–1840. <https://doi.org/10.1002/ijc.24146>
- van der Watt, P.J., Zemanay, W., Govender, D., Hendricks, D.T., Parker, M.I., and 1 other, 2014. Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma. *Oncol Rep* 32, 730–738. <https://doi.org/10.3892/or.2014.3231>
- Van Quickenberghe, E., De Sutter, D., van Loo, G., Eyckerman, S., Gevaert, K., 2018. A protein-protein interaction map of the TNF-induced NF-κB signal transduction pathway. *Sci Data* 5, 180289. <https://doi.org/10.1038/sdata.2018.289>
- Vanmeerbeek, I., Sprooten, J., De Ruyscher, D., Tejpar, S., Vandenberghe, P., and 6 others, 2020. Trial watch: chemotherapy-induced immunogenic cell death in immunology. *Oncol Immunology* 9, 1703449. <https://doi.org/10.1080/2162402X.2019.1703449>
- Vaquerezas, J.M., Kummerfeld, S.K., Teichmann, S.A., Luscombe, N.M., 2009. A census of human transcription factors: function, expression and evolution. *Nat Rev Genet* 10, 252–263. <https://doi.org/10.1038/nrg2538>
- Varfolomeev, E., Vucic, D., 2018. Intracellular regulation of TNF activity in health and disease. *Cytokine* 101, 26–32. <https://doi.org/10.1016/j.cyto.2016.08.035>
- Vazquez, A., Bond, E.E., Levine, A.J., Bond, G.L., 2008. The genetics of the p53 pathway, apoptosis and cancer therapy. *Nat Rev Drug Discov* 7, 979–987. <https://doi.org/10.1038/nrd2656>
- Verbeke, D., Demeyer, S., Prieto, C., de Bock, C.E., De Bie, J., and 10 others, 2020. The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. *Clin Cancer Res* 26, 5747–5758. <https://doi.org/10.1158/1078-0432.CCR-20-1315>

- Vessieres, A., 2019. CHAPTER 3. Iron Compounds as Anticancer Agents, in: Casini, A., Vessières, A., Meier-Menches, S.M. (Eds.), *Metallobiology*. Royal Society of Chemistry, Cambridge, pp. 62–90. <https://doi.org/10.1039/9781788016452-00062>
- Vessières, A., Wang, Y., McGlinchey, M.J., Jaouen, G., 2021. Multifaceted chemical behaviour of metallocene (M = Fe, Os) quinone methides. Their contribution to biology. *Coordination Chemistry Reviews* 430, 213658. <https://doi.org/10.1016/j.ccr.2020.213658>
- Vessières A., Quissac E., Lemaire N., Alentorn A., Domeracka P., Pigeon P., Sanson M., Idbaih A., Verreault M., 2021b, Heterogeneity of Response to Iron-Based Metalodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes, *Int. J. Mol. Sci. Int. J. Mol. Sci.* 2021, 22,10404. <https://doi.org/10.3390/ijms221910404>
- Vial, G., Detaille, D., Guigas, B., 2019. Role of Mitochondria in the Mechanism(s) of Action of Metformin. *Front Endocrinol (Lausanne)* 10, 294. <https://doi.org/10.3389/fendo.2019.00294>
- Vivanco, I., Sawyers, C.L., 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat Rev Cancer* 2, 489–501. <https://doi.org/10.1038/nrc839>
- Vonarbourg, A., Passirani, C., Saulnier, P., Benoit, J.-P., 2006. Parameters influencing the stealthiness of colloidal drug delivery systems. *Biomaterials* 27, 4356–4373. <https://doi.org/10.1016/j.biomaterials.2006.03.039>
- Waalder, J., Machon, O., Tumova, L., Dinh, H., Korinek, V., and 9 others. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. *Cancer Res* 72, 2822–2832. <https://doi.org/10.1158/0008-5472.CAN-11-3336>
- Wang, H., Li, F., Du, C., Wang, H., Mahato, R.I., and 1 other, 2014. Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. *Mol. Pharmaceutics* 11, 2600–2611. <https://doi.org/10.1021/mp400687w>
- Wang, Y., Pigeon, P., Top, S., Sanz García, J., Troufflard, C., and 3 others, 2019. Atypical Lone Pair- π Interaction with Quinone Methides in a Series of Imido-Ferrociphenol Anticancer Drug Candidates. *Angew. Chem. Int. Ed.* 58, 8421–8425. <https://doi.org/10.1002/anie.201902456>
- Wang, J.-Q.; Yang, Y., Cai, Q.-X., Cui, Q., Linn, J, Assaraf, Y.G., Chen, Z.-S., 2021. Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. *Drug Resist Updat* 54, 100743. <https://doi.org/10.1016/j.drup.2021.100743>
- Warfel, N.A., El-Deiry, W.S., 2014. HIF-1 signaling in drug resistance to chemotherapy. *Curr Med Chem* 21, 3021–3028. <https://doi.org/10.2174/0929867321666140414101056>
- Watanabe, K., Takatsuki, H., Sonoda, M., Tamura, S., Murakami, N., and 1 other, 2011. Anti-influenza viral effects of novel nuclear export inhibitors from *Valerianae Radix* and *Alpinia galanga*. *Drug Discov Ther* 5, 26–31. <https://doi.org/10.5582/ddt.v5.1.26>
- Wehn, P.M., Rizzi, J.P., Dixon, D.D., Grina, J.A., Schlachter, S.T., and 20 others, 2018. Design and Activity of Specific Hypoxia-Inducible Factor-2 α (HIF-2 α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). *J Med Chem* 61, 9691–9721. <https://doi.org/10.1021/acs.jmedchem.8b01196>
- Wei, J., Yang, Y., Lu, M., Lei, Y., Xu, L., and 6 others, 2018. Recent Advances in the Discovery of HIF-1 α -p300/CBP Inhibitors as Anti-Cancer Agents. *Mini Rev Med Chem* 18, 296–309. <https://doi.org/10.2174/1389557516666160630124938>
- Wei, N., Song, Y., Zhang, F., Sun, Z., Zhang, X., 2020. Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets. *Front Oncol* 10, 1424. <https://doi.org/10.3389/fonc.2020.01424>
- Wertz, I.E., 2014. TNFR1-activated NF- κ B signal transduction: regulation by the ubiquitin/proteasome system. *Curr Opin Chem Biol* 23, 71–77. <https://doi.org/10.1016/j.cbpa.2014.10.011>
- Wijdeven, R.H., Pang, B., Assaraf, Y.G., Neeffjes, J., 2016. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. *Drug Resist Updat* 28, 65–81. <https://doi.org/10.1016/j.drup.2016.07.001>
- Wong, R.P.C., Tsang, W.P., Chau, P.Y., Co, N.N., and 2 others, 2007. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. *Mol Cancer Ther* 6, 1054–1061. <https://doi.org/10.1158/1535-7163.MCT-06-0336>
- Workman, L.M., Habelhah, H., 2013. TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification. *Cell Signal* 25, 1654–1664. <https://doi.org/10.1016/j.cellsig.2013.04.005>
- Wortzel, I., Dror, S., Kenific, C.M., Lyden, D., 2019. Exosome-Mediated Metastasis: Communication from a Distance. *Developmental Cell* 49, 347–360. <https://doi.org/10.1016/j.devcel.2019.04.011>
- Wottrich, S., Kaufhold, S., Chrysos, E., Zoras, O., Baritaki, S., Bonavida, B., 2017 Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. *Drug Resist Updat* 30, 28–38. <https://doi.org/10.1016/j.drup.2017.01.001>
- Wu, Q., Zhou, L., Lv, D., Zhu, X., Tang, H., 2019. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. *J Hematol Oncol* 12, 53. <https://doi.org/10.1186/s13045-019-0739-0>
- Xie, T., Lim, S.M., Westover, K.D., Dodge, M.E., Ercan, D., and 10 others, 2014. Pharmacological targeting of the pseudokinase Her3. *Nat Chem Biol* 10, 1006–1012. <https://doi.org/10.1038/nchembio.1658>
- Xu, B., Zeng, M., Zeng, J., Feng, J., Yu, L., 2018. Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). *Medicine* 97, e13169. <https://doi.org/10.1097/MD.00000000000013169>
- Xu, D., Bum-Erdene, K., Si, Y., Zhou, D., Ghosyayel, M.K., and 1 other, 2017. Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists. *ChemMedChem* 12, 1794–1809. <https://doi.org/10.1002/cmdc.201700572>
- Yang, F., Teves, S.S., Kemp, C.J., Henikoff, S., 2014. Doxorubicin, DNA torsion, and chromatin dynamics. *Biochim Biophys Acta* 1845, 84–89. <https://doi.org/10.1016/j.bbcan.2013.12.002>
- Yao, Y., Dong, Y., Lin, F., Zhao, H., Shen, Z., and 4 others, 2009. The expression of CRM1 is associated with prognosis in human osteosarcoma. *Oncol Rep* 21, 229–235.
- Ye, Y., Li, B., 2006. 1'S-1'-acetoxychavicol acetate isolated from *Alpinia galanga* inhibits human immunodeficiency virus type 1 replication by blocking Rev transport. *J Gen Virol* 87, 2047–2053. <https://doi.org/10.1099/vir.0.81685-0>
- Yin, S., Kaluz, S., Devi, N.S., Jabbar, A.A., de Noronha, R.G., and 12 others, 2012. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 α interaction with cofactors p300/CBP. *Clin Cancer Res* 18, 6623–6633. <https://doi.org/10.1158/1078-0432.CCR-12-0861>
- Yoon, H., Liyanarachchi, S., Wright, F.A., Davuluri, R., Lockman, J.C., and 2 others, 2002. Nonlinear partial differential equations and applications: Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. *Proceedings of the National Academy of Sciences* 99, 15632–15637. <https://doi.org/10.1073/pnas.242597299>
- Yoshimura, M., Ishizawa, J., Ruvolo, V., Dilip, A., Quintás-Cardama, A., and 10 others, 2014. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in

mantle cell lymphoma. *Cancer Sci* 105, 795–801. <https://doi.org/10.1111/cas.12430>

Yu, M.K., Park, J., Jon, S., 2012. Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy. *Theranostics* 2, 3–44. <https://doi.org/10.7150/thno.3463>

Zanella, F., Renner, O., García, B. Callejas, S., Dopazo, A, Peregrina, S., and 2 others, 2010. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. *Oncogene* 29, 2973–2982. <https://doi.org/10.1038/onc.2010.58>

Zhang, J., Grek, C., Ye, Z.-W., Manevich, Y., Tew, K.D., and 1 other, 2014. Pleiotropic functions of glutathione S-transferase P. *Adv Cancer Res* 122, 143–175. <https://doi.org/10.1016/B978-0-12-420117-0.00004-9>

Zhao, L., Vogt, P.K., 2008. Class I PI3K in oncogenic cellular transformation. *Oncogene* 27, 5486–5496. <https://doi.org/10.1038/onc.2008.244>

Zheng, J., Trafny, E.A., Knighton, D.R., Xuong, N.H., Taylor, S.S., and 2 others, 1993. 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. *Acta Crystallogr D Biol Crystallogr* 49, 362–365. <https://doi.org/10.1107/S0907444993000423>

Zheng, Y., Gery, S., Sun, H., Shacham, S., Kauffman, M., and 1 other, 2014. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. *Cancer Chemother Pharmacol* 74, 487–495. <https://doi.org/10.1007/s00280-014-2495-8>

Zhou, F., Qiu, W., Yao, R., Xiang, J., Sun, X., and 3 others, 2013. CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. *Med Oncol* 30, 726. <https://doi.org/10.1007/s12032-013-0726-1>

Zhu, Q., Sun, F., Li, T., Zhou, M., Ye, J., and 6 others, 2021. Engineering Oxaliplatin Prodrug Nanoparticles for Second Near-Infrared Fluorescence Imaging-Guided Immunotherapy of Colorectal Cancer. *Small* 17, 2007882. <https://doi.org/10.1002/smll.202007882>

Zhu, Y., Jia, H., Duan, Q., Wu, F., 2021. Nanomedicines for combating multidrug resistance of cancer. *WIREs Nanomed Nanobiotechnol*. <https://doi.org/10.1002/wnan.1715>